viral
infect
import
caus
diseas
respiratori
tract
common
cold
frequent
encount
infecti
syndrom
human
influenza
continu
major
caus
mortal
seriou
morbid
worldwid
respiratori
viral
infect
frequent
complic
cours
patient
chronic
obstruct
pulmonari
diseas
copd
asthma
number
immunocompromis
person
popul
increas
infect
due
cytomegaloviru
herp
virus
adenovirus
paramyxovirus
assum
increas
import
pulmonari
medicin
final
recent
year
seen
emerg
new
viral
respiratori
pathogen
includ
hantavirus
human
metapneumoviru
avian
influenza
virus
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
coronavirus
introductori
section
outlin
gener
concept
respiratori
viral
infect
associ
clinic
syndrom
follow
section
provid
review
major
viral
pathogen
infect
respiratori
tract
virus
import
respiratori
tract
tabl
includ
consid
princip
respiratori
virus
replic
gener
restrict
respiratori
tract
other
respiratori
involv
part
gener
infect
viru
classif
depend
part
type
configur
nucleic
acid
viral
genom
characterist
viral
structur
protein
presenc
absenc
envelop
surround
viru
particl
number
distinct
antigen
type
within
viru
famili
also
vari
rout
differ
respiratori
virus
spread
person
person
variabl
includ
combin
contact
droplet
aerosol
transmiss
exampl
rhinoviru
respiratori
syncyti
viru
rsv
primarili
spread
direct
contact
contamin
skin
environment
surfac
follow
selfinocul
viru
onto
nasal
mucosa
conjunctiva
virus
measl
varicellazost
virus
spread
smallparticl
aerosol
virus
may
spread
mean
largerparticl
aerosol
short
distanc
rel
import
variou
transmiss
rout
natur
condit
viru
vari
mani
case
unknown
initi
site
infect
pathogenesi
differ
variou
viru
group
rhinoviru
associ
mainli
upper
respiratori
tract
involv
other
influenza
commonli
invad
lower
airway
sometim
pulmonari
parenchyma
addit
caus
upper
airway
diseas
virus
also
differ
rel
contribut
clinic
manifest
diseas
damag
due
direct
viral
mechan
damag
due
host
immun
respons
inflamm
addit
import
featur
respiratori
viru
infect
effect
resid
bacteri
flora
upper
airway
respiratori
viru
infect
alter
bacteri
colon
pattern
increas
bacteri
adhes
respiratori
epithelium
reduc
mucociliari
clearanc
phagocytosi
impair
host
defens
virus
allow
colon
pathogen
bacteria
invas
normal
steril
area
paranas
sinus
middl
ear
lower
respiratori
tract
result
secondari
infect
shown
tabl
univers
accept
standard
definit
cold
term
usual
use
refer
acut
rhiniti
variabl
degre
pharyng
system
complaint
absent
modest
sever
fever
unusu
allerg
diseas
upper
airway
often
clinic
manifest
similar
cold
cold
frequent
associ
involv
middl
ear
like
due
virus
caus
cold
case
pharyng
symptom
predomin
degre
overshadow
complaint
kinin
potent
stimul
pain
nerv
end
high
level
bradykinin
lysylbradykinin
present
nasal
secret
patient
rhinovirusinduc
cold
intranas
applic
bradykinin
promot
sore
throat
nasal
symptom
volunt
support
role
agent
pathogenesi
cold
symptom
respiratori
virus
caus
pharyng
divid
two
group
associ
pharyng
tonsillar
exud
without
exud
tabl
pharyng
often
promin
complaint
adenoviru
influenza
viru
infect
also
eustachian
tube
dysfunct
cold
associ
symptomat
otiti
media
approxim
case
adult
higher
proport
young
children
cold
frequent
associ
sinu
mucos
thicken
secret
comput
tomographi
scan
rare
result
symptomat
sinus
vertigo
associ
viral
labyrinth
may
also
seen
common
cold
syndrom
caus
one
larg
number
antigen
distinct
virus
found
four
princip
group
tabl
epidemiolog
studi
indic
annual
basi
one
antigen
type
viru
respons
less
cold
sinc
discoveri
respiratori
virus
rhinoviru
emerg
prototyp
common
cold
viru
fig
recommend
approach
cold
use
individu
remedi
treat
specif
symptom
nasal
spray
contain
decongest
use
day
avoid
rebound
vasomotor
rhiniti
cough
syrup
contain
expector
unproven
valu
common
cold
symptom
sneez
rhinorrhea
allevi
nonselect
antihistamin
brompheniramin
chlorpheniramin
clemastin
fumar
treatment
select
h
inhibitor
effect
studi
pseudoephedrin
demonstr
measur
improv
nasal
air
flow
consist
decongest
effect
nonsteroid
antiinflammatori
drug
naproxen
moder
system
symptom
rhinoviru
infect
howev
use
decongest
phenylpropanolamin
shown
associ
increas
risk
hemorrhag
stroke
topic
applic
ipratropium
quaternari
anticholinerg
agent
minim
absorb
across
biolog
membran
reduc
rhinorrhea
significantli
natur
occur
cold
agent
probabl
exert
major
effect
parasympathet
regul
mucou
seromuc
gland
importantli
overthecount
cough
cold
remedi
studi
pediatr
popul
may
associ
signific
side
effect
pharyng
often
present
part
common
cold
syndrom
thu
usual
associ
dextromethorphan
suppress
night
time
cough
honey
administ
infant
younger
due
risk
infant
botul
clinic
syndrom
influenza
character
rapid
onset
constitut
symptom
includ
fever
chill
prostrat
muscl
ach
headach
concurr
follow
upper
lower
respiratori
tract
symptom
system
symptom
tend
domin
first
sever
day
ill
wherea
respiratori
complaint
particularli
cough
predomin
later
first
week
ill
photophobia
excess
tear
pain
eye
movement
common
earli
ill
mild
conjunct
clear
nasal
discharg
without
obstruct
pharyng
inject
small
tender
cervic
lymph
node
frequent
present
fever
may
peak
c
c
higher
last
day
persist
nonproduct
cough
easi
fatig
asthenia
common
second
week
ill
influenza
type
b
virus
import
caus
influenza
syndrom
particularli
ill
present
epidem
form
howev
syndrom
also
seen
associ
infect
virus
includ
adenoviru
parainfluenza
rsv
characterist
clinic
featur
influenza
epidem
natur
usual
permit
practition
make
accur
diagnosi
recogn
epidem
influenza
viru
infect
particularli
cough
fever
present
specif
antivir
therapi
effect
given
earli
cours
ill
see
section
influenza
viru
symptomat
treatment
bed
rest
oral
hydrat
antipyret
antituss
also
benefici
fever
treat
certain
clinic
situat
children
previou
febril
convuls
patient
preexist
cardiac
diseas
possibl
associ
rey
syndrom
aspirin
must
avoid
pediatr
patient
croup
syndrom
children
character
unusu
brassi
bark
cough
see
audio
may
accompani
inspiratori
stridor
dyspnea
hoars
symptom
often
preced
sever
day
upper
respiratori
ill
typic
wors
night
croup
seen
primarili
children
younger
term
acut
infecti
croup
laryngotracheobronch
appli
contagi
diseas
affect
otherwis
healthi
children
often
associ
respiratori
ill
famili
term
acut
spasmod
croup
appli
similar
syndrom
common
young
children
prone
recurr
attack
precipit
respiratori
viral
infect
possibl
allerg
factor
children
fever
frequent
absent
symptom
often
abat
within
sever
hour
children
acut
laryngotracheobronch
symptom
decreas
intens
sever
day
manag
home
howev
increas
laryng
obstruct
associ
respiratori
insuffici
manifest
restless
air
hunger
stridor
virus
associ
type
enanthem
mean
lesion
mucou
membran
vesicl
ulcer
coxsacki
virus
associ
condit
herpangina
pain
often
febril
pharyng
children
young
adult
character
vesicular
lesion
soft
palat
virus
herp
famili
caus
small
proport
case
pharyng
primari
infect
herp
simplex
viru
manifest
acut
vesiculoulc
pharyng
gingivostomat
may
exud
charact
immunocompromis
patient
herp
simplex
viru
caus
larg
shallow
ulcer
mucosa
chronic
progress
untreat
epsteinbarr
viru
mononucleosi
characterist
acut
exud
pharyng
mononucleosi
due
cytomegaloviru
infect
may
nonexud
pharyng
acut
chronic
rare
cytomegaloviru
caus
oral
ulcer
immunosuppress
patient
pharyng
aris
primari
infect
human
immunodefici
viru
hiv
virus
hemorrhag
fever
group
produc
acut
pharyng
earli
diseas
skin
lesion
appear
exud
pharyng
common
clinic
manifest
lassa
fever
typic
sore
throat
accompani
nasal
symptom
like
viral
natur
infect
mix
anaerob
bacteria
vincent
angina
corynebacterium
diphtheria
also
differenti
diagnosi
exud
pharyng
treatment
case
viral
pharyng
symptomat
diagnosi
acut
bronchiti
usual
appli
case
acut
respiratori
diseas
sever
prolong
cough
continu
sign
symptom
acut
infect
subsid
cough
appear
first
week
ill
rhinoviru
cold
young
adult
case
influenza
viru
infect
often
prolong
adenoviru
infect
characterist
involv
tracheobronchi
tree
result
bronchiti
militari
popul
part
syndrom
acut
respiratori
diseas
mechan
cough
product
viral
infect
well
understood
may
includ
direct
damag
respiratori
mucosa
releas
inflammatori
substanc
respons
infect
increas
product
andor
decreas
clearanc
respiratori
secret
stimul
airway
irrit
receptor
intranas
applic
sever
prostaglandin
also
produc
cough
uninfect
volunt
infect
may
also
enhanc
airway
reactiv
lead
increas
sensit
cold
air
pollut
smoke
differenti
diagnosi
acut
bronchiti
includ
nonvir
infect
noninfecti
etiolog
coughvari
asthma
bordetella
pertussi
mycoplasma
pneumonia
chlamydia
pneumonia
infect
caus
prolong
cough
otherwis
healthi
person
workup
acut
cough
direct
toward
determin
presenc
pneumonia
present
treatment
antibacteri
agent
benefit
symptomat
treatment
direct
suppress
cough
children
singl
nocturn
dose
honey
effect
ment
oxygen
steroid
shown
confer
signific
benefit
manag
mild
moder
sever
croup
includ
rapid
improv
symptom
reduc
length
hospit
stay
reduc
rate
intub
administr
singledos
steroid
therapi
set
associ
signific
side
effect
probabl
use
patient
ill
enough
requir
emerg
depart
clinic
visit
antivir
agent
test
efficaci
situat
although
potenti
benefit
antivir
therapi
typic
selflimit
cours
croup
would
like
limit
sinc
croup
viral
ill
antibiot
therapi
benefit
bronchiol
acut
inflammatori
disord
small
airway
character
obstruct
air
trap
hyperinfl
lung
atelectasi
typic
seen
children
younger
severalday
prodrom
mild
upper
respiratori
tract
symptom
patient
typic
present
inspiratori
expiratori
wheez
clinic
featur
includ
tachypnea
intercost
suprastern
retract
nasal
flare
hyperreson
chest
wheez
inspiratori
rale
usual
lead
accur
clinic
diagnosi
infant
often
afebril
mild
case
symptom
resolv
within
sever
day
chest
radiograph
show
increas
lung
volum
flatten
diaphragm
peribronchi
thicken
efig
often
atelectasi
parenchym
consolid
indic
concurr
bronchopneumonia
fig
chest
comput
tomographi
ct
may
show
bronchial
wall
thicken
area
increas
attenu
repres
atelectasi
mix
area
decreas
attenu
due
small
airway
inflamm
obstruct
produc
air
trap
efig
white
blood
cell
count
differenti
count
usual
within
normal
limit
rest
use
accessori
muscl
intercost
retract
may
follow
develop
exhaust
sever
hypoventil
cyanosi
cardiovascular
collaps
fluctuat
cours
typic
radiolog
examin
upper
airway
show
glottic
subglott
edema
fig
efig
help
differenti
disord
acut
bacteri
epiglott
howev
radiograph
limit
accuraci
diagnosi
uncertain
radiolog
pharyng
examin
avoid
risk
cardiorespiratori
arrest
acut
epiglott
emerg
assess
otolaryngologist
anesthesiologist
indic
situat
acut
infecti
croup
syndrom
associ
princip
infect
one
parainfluenza
virus
well
rsv
influenza
b
virus
adenovirus
rhinoviru
measl
import
caus
sever
croup
develop
world
influenza
epidem
also
associ
sever
croup
differenti
diagnosi
croup
includ
acut
bacteri
epiglott
diphtherit
croup
asthma
intrins
extrins
upper
airway
obstruct
relat
aspir
foreign
bodi
allerg
angioedema
retropharyng
abscess
major
hospit
children
hypoxem
oxygen
mainstay
treatment
sever
diseas
humidifi
air
mist
therapi
commonli
use
valu
mist
therapi
proven
remov
child
parent
placement
mist
tent
distress
benefici
child
administr
nebul
racem
epinephrin
commonli
use
symptomat
relief
croup
believ
stimul
drug
caus
mucos
vasoconstrict
lead
decreas
subglott
edema
onset
action
rapid
often
within
minut
durat
relief
also
limit
last
hour
less
therefor
treat
subject
observ
close
clinic
deterior
although
symptomat
relief
consider
use
epinephrin
associ
improv
b
mani
patient
acut
viral
infect
also
viral
infect
may
complic
secondari
bacteri
pneumonia
invas
procedur
would
necessari
differenti
among
pure
viral
pneumonia
secondari
bacteri
pneumonia
mix
viral
bacteri
infect
rel
import
differ
virus
caus
pneumonia
depend
season
age
distribut
popul
studi
outbreak
influenza
viru
account
viral
pneumonia
adult
addit
rsv
adenoviru
parainfluenza
viru
varicella
viru
caus
pneumonia
normal
adult
unusu
virus
continu
emerg
epidem
sever
acut
pneumon
includ
hantaviru
coronaviru
sar
avian
influenza
virus
children
rsv
parainfluenza
viru
adenoviru
addit
influenza
virus
import
caus
pneumonia
measl
viru
pneumonia
affect
children
adult
epidem
suscept
popul
report
case
pneumonia
adult
children
attribut
rhinoviru
evid
virus
definit
caus
pneumonia
circumstanti
clinic
radiograph
featur
sporad
case
viral
pneumonia
usual
suffici
characterist
permit
specif
viral
diagnosi
differenti
bacteri
pneumonia
clinic
ground
alon
except
includ
measl
efig
varicella
pneumonia
associ
rash
establish
diagnosi
therefor
attent
first
direct
exclud
primari
secondari
bacteri
pneumonia
test
detect
viral
antigen
nucleic
acid
increasingli
avail
rapidli
adopt
prefer
approach
establish
etiolog
diagnosi
b
see
chapter
treatment
viral
pneumonia
normal
host
support
natur
direct
earli
antimicrobi
therapi
secondari
bacteri
infect
present
specif
antivir
therapi
may
benefici
discuss
individu
pathogen
viral
pneumonia
extens
involv
lung
tissu
may
requir
prolong
ventilatori
assist
pulmonari
rehabilit
case
viral
pneumonia
rapid
relentless
fatal
cours
gener
alveolar
interstiti
opac
develop
adult
respiratori
distress
syndrom
ard
progress
respiratori
failur
viral
pneumonia
import
problem
increas
number
person
popul
defici
immun
result
cytotox
chemotherapi
organ
transplant
acquir
immunodefici
syndrom
aid
major
respiratori
virus
affect
normal
person
may
also
caus
pneumonia
impair
host
sever
prolong
pneumonia
due
adenoviru
respiratori
syncyti
influenza
measl
parainfluenza
viru
develop
patient
immunocompromis
patient
also
shed
respiratori
virus
prolong
period
thu
respons
extens
transmiss
infect
other
addit
individu
may
develop
pneumonia
due
virus
cytomegaloviru
rare
caus
lower
respiratori
tract
major
case
etiolog
agent
identifi
associ
rsv
virus
associ
bronchiol
includ
human
metapneumoviru
bocaviru
parainfluenza
viru
influenza
b
virus
adenoviru
measl
rhinovirus
major
differenti
diagnost
consider
asthma
uncommon
children
younger
one
year
old
correct
hypoxemia
import
aspect
manag
lower
respiratori
tract
diseas
studi
corticosteroid
therapi
found
consist
benefit
studi
bronchodil
reach
conflict
result
bronchodil
drug
may
contribut
increas
restless
cardiovascular
stress
guidelin
suggest
bronchodil
use
routin
one
recent
random
trial
suggest
ondemand
use
inhal
racem
adrenalin
may
result
decreas
length
stay
infant
hospit
bronchiol
dehydr
effect
tachypnea
reduc
oral
intak
hospit
infant
parenter
rehydr
often
necessari
care
must
taken
avoid
induc
hyponatremia
aerosol
treatment
synthet
nucleosid
ribavirin
associ
reduct
viru
titer
inconsist
clinic
benefit
antibacteri
drug
includ
azithromycin
benefit
virus
import
caus
pneumonia
adult
children
associ
radiograph
proven
pneumonia
hospit
adult
estim
caus
total
pneumonia
pediatr
outpati
hospit
infant
figur
may
underestim
import
viral
infect
caus
pneumonia
particularli
outpati
insensit
viral
diagnost
method
lack
chest
radiograph
routin
infect
infant
young
children
prolong
asymptomat
viral
shed
respiratori
gastrointestin
gi
tract
type
includ
often
implic
respiratori
diseas
eg
type
acquir
later
life
characterist
epidem
set
instanc
viral
transmiss
probabl
take
place
direct
contact
infecti
secret
howev
explos
natur
adenovir
acut
respiratori
diseas
militari
recruit
probabl
reflect
airborn
spread
commun
adenoviru
respiratori
diseas
recogn
summer
month
associ
outbreak
sporad
case
febril
pharyng
bronchiti
nosocomi
outbreak
adenoviru
infect
arisen
hospit
ward
special
care
unit
psychiatr
facil
new
variant
adenoviru
occasion
emerg
associ
outbreak
worldwid
sinc
specif
variant
adenoviru
type
respons
sever
civilian
outbreak
larg
militari
outbreak
recent
adenoviru
type
previous
rare
serotyp
respons
outbreak
diseas
militari
civilian
popul
case
rel
mild
febril
respiratori
ill
case
seen
sever
pneumonia
requir
hospit
infect
adenoviru
type
associ
weight
gain
mice
serolog
posit
serotyp
appear
common
adult
children
obes
adenovirus
isol
upper
airway
eye
urin
stool
rare
blood
incub
period
natur
acquir
adenoviru
diseas
respiratori
tract
usual
day
may
week
cytopatholog
chang
also
observ
bronchial
epitheli
cell
crystallin
array
viru
particl
found
alveolar
line
cell
infect
person
sever
ill
extent
damag
respiratori
tract
nonfat
adenoviru
respiratori
diseas
well
defin
may
result
combin
direct
viral
mechan
hostrel
inflammatori
respons
infect
case
fatal
adenoviru
pneumonia
bronchial
epitheli
necrosi
bronchial
obstruct
interstiti
pneumonia
seen
cell
contain
larg
basophil
intranuclear
inclus
socal
smudg
cell
appear
characterist
lung
transplant
recipi
necrot
bronchocentr
pneumonia
diffus
alveolar
damag
report
adenoviru
respiratori
diseas
nonpneumon
respiratori
syndrom
associ
adenoviru
infect
includ
acut
respiratori
diseas
militari
recruit
pharyngoconjunctiv
fever
civilian
similar
characterist
fig
adenoviru
respiratori
diseas
typic
involv
pharynx
moder
sever
sometim
purul
pharyng
also
characterist
diseas
mark
tracheiti
bronchiti
tracheobronch
well
rhiniti
conjunct
conjunct
featur
infect
major
respiratori
diseas
normal
host
cytomegaloviru
caus
sever
primari
viral
pneumonia
see
efig
well
predispos
patient
bacteri
fungal
superinfect
immunosuppress
effect
varicellazost
herp
simplex
viru
pneumonia
rel
uncommon
seriou
infect
immunosuppress
patient
adenoviru
mediums
nm
nonenvelop
viru
genom
compos
linear
doublestrand
dna
fig
current
antigen
type
adenoviru
associ
human
infect
although
type
associ
human
diseas
protein
coat
viru
compos
hexagon
pentagon
capsomer
icosahedr
array
long
project
fiber
vertex
fiber
thought
site
host
cell
attach
adenovirus
type
coxsacki
b
virus
use
receptor
design
coxsacki
viru
adenoviru
receptor
car
whose
usual
function
mediat
cell
interact
extracellular
matrix
protein
adenovirus
use
complement
regulatori
protein
cellular
receptor
viru
entri
cell
also
promot
interact
penton
base
viru
alphav
integrin
viral
typespecif
antigen
give
rise
neutral
antibodi
present
hexon
fiber
capsid
hexon
also
contain
complementfix
antigen
crossreact
among
mammalian
adenovirus
adenovirus
caus
human
diseas
nonhuman
reservoir
although
nonhuman
adenovirus
found
speci
serotyp
especi
type
popul
seen
sporad
case
young
children
adenoviru
infect
associ
mild
febril
respiratori
ill
associ
otiti
media
approxim
case
adenoviru
first
recogn
caus
viral
pneumonia
militari
recruit
sinc
recogn
rare
caus
pneumonia
civilian
adult
efig
children
clinic
characterist
adenoviru
pneumonia
similar
pneumonia
difficult
make
accur
etiolog
diagnosi
basi
clinic
featur
fatal
case
extens
pulmonari
damag
death
interven
week
ill
intravascular
coagulopathi
also
late
featur
case
septic
shock
pictur
describ
adenovirus
caus
particularli
aggress
form
pneumonia
neonat
character
necrot
bronchiol
alveol
viru
may
acquir
mother
perhap
via
birth
canal
longterm
sequela
adenoviru
infect
may
includ
persist
radiograph
abnorm
abnorm
pulmonari
function
test
bronchiectasi
bronchiol
obliteran
immun
adenovirus
caus
fatal
pneumonia
dissemin
infect
hepat
hemorrhag
cystiti
renal
failur
transplant
patient
immunodefici
person
variou
immunotyp
recov
patient
etabl
includ
higher
number
serotyp
seen
patient
type
seen
particular
frequenc
includ
clinic
import
recoveri
adenoviru
patient
particularli
stool
sampl
often
difficult
determin
immunodefici
patient
may
shed
adenovirus
absenc
overt
diseas
caus
although
diagnosi
tradit
achiev
viru
cultur
viral
antigen
nucleic
acid
detect
directli
appropri
specimen
respiratori
secret
conjunctiv
swab
stool
urin
depend
clinic
syndrom
rapid
detect
viral
antigen
clinic
specimen
elisa
immunofluoresc
viral
dna
nucleic
acid
amplif
techniqu
increasingli
use
instead
viral
cultur
fastidi
serotyp
slow
rate
isol
see
chapter
quantit
measur
adenoviru
dna
level
plasma
may
use
diagnosi
respons
therapi
frozen
specimen
c
satisfactori
test
rel
stabil
adenovirus
cell
cultur
cytopath
effect
usual
appear
day
may
take
sever
week
thu
limit
util
viral
cultur
guid
clinic
manag
time
requir
detect
viru
cell
cultur
shorten
littl
day
employ
centrifug
cultur
system
serodiagnosi
reli
primarili
test
groupspecif
complementfix
antibodi
respons
use
acut
convalesc
serum
specimen
howev
infect
adenoviru
type
detect
virus
therefor
present
use
diagnost
find
adenoviru
respiratori
diseas
adenoviru
respiratori
diseas
conjunct
typic
mild
follicular
although
adenoviru
type
also
caus
sever
condit
epidem
keratoconjunct
fever
chill
myalgia
prostrat
promin
featur
adenoviru
infect
often
perceiv
patient
flulik
ill
unusu
sever
cold
case
acut
respiratori
diseas
tend
tracheobronch
perhap
reflect
acquisit
infect
airborn
rout
convers
pharyngoconjunctiv
fever
infrequ
cough
tracheobronchi
complaint
outbreak
may
reflect
infect
contract
pharyng
andor
conjunctiv
inocul
viru
contamin
water
two
syndrom
associ
viral
serotyp
civilian
viral
replicas
proteinas
particularli
proteinas
also
antivir
drug
target
human
coronavirus
recogn
caus
common
cold
mani
year
caus
frequent
reinfect
throughout
life
adult
virus
account
acut
respiratori
diseas
annual
peak
period
annual
ill
rate
children
reach
peak
rate
polymeras
chain
reaction
pcr
techniqu
appli
sampl
collect
year
children
younger
coronavirus
associ
lower
respiratori
tract
episod
upper
respiratori
tract
ill
per
personyear
report
frequenc
infect
adult
virus
rang
per
person
per
year
infect
seen
person
prior
antibodi
infect
viru
coronavirus
usual
circul
winter
earli
spring
detect
yearround
novel
coronavirus
recent
associ
sever
respiratori
diseas
outbreak
around
world
sar
emerg
southern
china
quickli
spread
global
caus
viru
subsequ
name
sarscov
ultim
least
probabl
case
sever
respiratori
diseas
death
age
attribut
sar
worldwid
outbreak
termin
sourc
outbreak
believ
anim
reservoir
civet
cat
recent
second
outbreak
coronaviru
sever
respiratori
ill
recogn
case
primarili
found
middl
eastern
countri
may
first
case
mer
confirm
travel
saudi
arabia
unit
state
second
case
identifi
travel
saudi
arabia
florida
two
case
link
viru
respons
mer
name
merscov
genet
close
relat
coronavirus
found
bat
evid
indic
merscov
also
infect
camel
role
transmiss
human
remain
defin
inform
merscov
activ
evolv
current
inform
found
http
wwwcdcgovcoronavirusm
coronavirus
transmiss
like
involv
close
contact
inocul
respiratori
tract
infecti
secret
via
larg
droplet
demonstr
human
challeng
experi
anim
studi
sarscov
sarscov
viru
shed
peak
day
symptom
onset
height
diseas
sever
phenomenon
account
preponder
transmiss
hospit
featur
allow
outbreak
control
infect
control
procedur
incub
period
sar
estim
day
convent
human
coronavirus
day
convent
coronaviru
antigen
detect
epitheli
cell
shed
nasopharynx
infect
volunt
experiment
infect
nasal
airway
resist
mucos
temperatur
albumin
content
nasal
secret
increas
howev
rel
littl
complementfix
test
biopsi
specimen
appear
characterist
intranuclear
basophil
inclus
bodi
seen
light
microscopi
crystallin
array
viru
seen
electron
microscopi
use
histopatholog
diagnosi
antivir
treatment
adenoviru
infect
proven
valu
ganciclovir
cidofovir
activ
vitro
increas
number
report
indic
intraven
ganciclovir
may
use
serious
ill
patient
although
expens
signific
renal
toxic
cidofovir
also
use
treatment
presumpt
therapi
adenoviru
infect
highrisk
immunocompromis
patient
although
intraven
ribavirin
activ
group
c
adenovirus
vitro
ribavirin
combin
immunoglobulin
use
individu
patient
failur
common
promin
fever
system
complaint
associ
adenoviru
respiratori
diseas
analges
aspirin
acetaminophen
need
often
milder
coryz
ill
rhinoviru
cold
warm
salin
gargl
help
reliev
throat
pain
usual
requir
narcot
presenc
pharyng
exud
may
sometim
lead
incorrect
diagnosi
streptococc
pharyng
result
initi
antimicrobi
therapi
effect
safe
live
oral
vaccin
adenoviru
type
develop
militari
use
deliv
entericco
capsul
control
acut
respiratori
diseas
recruit
popul
use
vaccin
associ
replac
nonvaccin
serotyp
manufactur
vaccin
discontinu
adenovirus
reemerg
import
caus
acut
respiratori
diseas
popul
new
vaccin
subsequ
introduc
coronavirus
envelop
virus
contain
singlestrand
positivesens
ribonucl
acid
rna
genom
approxim
nucleotid
distinct
clubshap
project
present
viru
surfac
give
appear
crown
corona
deriv
name
coronavirus
classifi
four
genera
alpha
beta
gamma
delta
beta
genu
subdivid
four
lineag
ad
human
coronaviru
strain
hcov
hcov
member
alpha
genu
human
strain
hcov
member
beta
genu
novel
coronavirus
sarscov
merscov
also
member
beta
genu
lineag
b
c
respect
viru
contain
five
structur
protein
spike
protein
hemagglutininesteras
matrix
e
envelop
n
nucleocapsid
spike
protein
major
envelop
glycoprotein
mediat
attach
cell
fusion
cell
membran
antibodi
spike
protein
thought
associ
protect
thu
candid
therapeut
vaccin
target
second
envelop
protein
found
coronaviru
strain
nonstructur
protein
effect
immun
shortterm
rechalleng
homotyp
viru
serotyp
result
infect
ill
addit
certain
circumst
vaccin
anim
coronavirus
led
enhanc
diseas
taken
consider
deter
effort
develop
efficaci
sarscov
vaccin
current
avail
antivir
agent
demonstr
clinic
activ
coronavirus
human
agent
potenti
activ
sarscov
includ
chloroquin
proteas
inhibitor
ribavirin
type
interferon
niclosamid
antiinflammatori
agent
indomethacin
ribavirin
combin
lopinavirritonavir
proteas
inhibitor
use
hiv
diseas
associ
lower
incid
advers
outcom
compar
histor
control
ribavirin
alon
one
studi
nelfinavir
anoth
proteas
inhibitor
also
demonstr
vitro
antivir
activ
target
control
sar
viral
replic
includ
interferon
although
mechan
unknown
chloroquin
niclosamid
indomethacin
inhibit
sarscov
vitro
cytomegaloviru
cytomegaloviru
cmv
member
gammaherpesviru
subfamili
herp
virus
structur
biochem
characterist
includ
intern
core
contain
linear
doublestrand
dna
icosadeltahedr
capsid
contain
capsomer
envelop
deriv
hostcel
nuclear
membran
howev
larg
size
cmv
virion
nm
larger
genom
bp
distinguish
human
herp
virus
approxim
homolog
genom
variou
strain
cmv
suffici
differ
exist
permit
strain
identif
restrict
endonucleas
analysi
cmv
genom
code
approxim
structur
protein
function
mani
current
unknown
addit
clinic
isol
often
encod
multipl
gene
product
seen
laboratori
strain
envelop
glycoprotein
b
h
identifi
major
antigen
elicit
neutral
antibodi
glycoprotein
b
may
also
target
cytotox
lymphocyt
respons
multipl
protein
also
serv
target
tcell
respons
cmvspecif
cytotox
tcell
respons
import
host
defens
mechan
associ
surviv
cmv
infect
bone
marrow
transplant
recipi
howev
cmv
use
multipl
mechan
includ
downregul
hla
class
cell
surfac
interfer
antigen
process
evad
recognit
host
infect
cmv
whether
symptomat
follow
prolong
excret
viru
urin
saliva
stool
tear
breast
milk
vagin
secret
semen
thu
major
reservoir
cmv
asymptomat
infect
person
viru
shed
persist
year
children
congenit
perinat
cmv
infect
viru
believ
transmit
direct
contact
especi
condit
intimaci
found
child
care
center
famili
set
thu
rate
acquisit
infect
known
pathogenesi
common
cold
induc
convent
human
coronavirus
hallmark
pulmonari
patholog
fatal
case
sar
diffus
alveolar
damag
type
ii
pneumocyt
hyperplasia
squamou
metaplasia
multinucl
giant
cell
hemophagocytosi
phagocytosi
erythrocyt
leukocyt
platelet
histiocyt
report
potenti
consequ
cytokin
dysregul
furthermor
viru
detect
within
pulmonari
epitheli
cell
find
postul
diseas
pathogenesi
involv
direct
damag
pulmonari
epithelia
viru
combin
excess
dysregul
host
immun
respons
convent
human
coronavirus
produc
typic
coryz
ill
indistinguish
cold
due
virus
coronavirus
also
link
acut
otiti
media
exacerb
asthma
children
exacerb
chronic
bronchiti
pneumonia
adult
contrast
sar
nonspecif
present
difficult
distinguish
viral
acut
respiratori
ill
particularli
influenza
common
symptom
present
fever
chill
andor
rigor
myalgia
occasion
diarrhea
cough
dyspnea
predomin
respiratori
symptom
may
present
initi
respiratori
diseas
becom
sever
day
patient
requir
respiratori
support
mer
similar
present
although
gi
symptom
may
promin
sar
fatal
rate
age
higher
older
adult
children
milder
diseas
similarli
major
recogn
case
mer
date
individu
comorbid
sar
laboratori
abnorm
includ
elev
lactat
dehydrogenas
transaminas
creatin
kinas
well
hematolog
abnorm
particularli
lymphopenia
deplet
cell
thrombocytopenia
common
find
chest
ct
includ
unilater
bilater
area
groundglass
opacif
interlobular
septal
intralobular
interstiti
thicken
patient
peripher
involv
lower
lung
zone
observ
case
recoveri
acut
ill
pulmonari
fibrosi
develop
clinic
featur
predict
poor
outcom
includ
presenc
bilater
diseas
present
markedli
elev
lactat
dehydrogenas
older
age
comorbid
condit
main
site
viral
replic
sarscov
appear
lower
respiratori
tract
pcr
detect
reliabl
sputum
viral
rna
also
detect
blood
stool
serum
antibodi
rise
within
week
ill
although
measur
week
becom
standard
exclud
sar
immun
coronavirus
appear
shortliv
epidemiolog
studi
coronaviru
infect
demonstr
high
reinfect
rate
human
volunt
experi
infect
coronaviru
induc
nucleosi
immunocompromis
host
may
varieti
clinic
syndrom
sever
impact
whether
infect
acquir
de
novo
repres
reactiv
endogen
viru
risk
sever
diseas
particularli
high
transplant
patient
cmvseroneg
recipi
receiv
organ
seroposit
donor
pathogenesi
cmv
pneumonia
partli
relat
viral
replic
also
thought
immunopatholog
basi
develop
cmv
pneumon
reflect
complex
interact
viral
infect
graftversushost
diseas
particularli
marrow
transplant
recipi
see
chapter
two
pattern
histopatholog
describ
lung
tissu
bone
marrow
transplant
patient
seriou
pneumonia
one
miliari
pattern
multipl
focal
lesion
show
extens
cytomegali
local
necrosi
alveolar
hemorrhag
fibrin
deposit
neutrophil
respons
see
fig
interstiti
pattern
alveolar
cell
hyperplasia
interstiti
edema
lymphoid
infiltr
diffus
distribut
cytomegal
cell
cytomegaloviru
caus
varieti
human
diseas
includ
congenit
perinat
infect
infecti
mononucleosi
hepat
posttransfus
infect
invas
infect
patient
impair
immun
transplant
popul
cmv
infect
often
involv
multipl
organ
system
conjunct
opportunist
infecti
agent
viru
rare
caus
pneumonia
healthi
host
main
impact
cmv
respiratori
pathogen
immunocompromis
patient
recipi
allogen
bone
marrow
transplant
cmv
common
infecti
caus
interstiti
pneumonia
untreat
respons
highest
fatal
rate
risk
cmv
pneumonia
greatest
day
bone
marrow
transplant
howev
lateonset
cmv
syndrom
day
posttransplant
increasingli
recogn
effect
control
earlieronset
diseas
risk
factor
diseas
includ
advanc
age
presenc
acut
graftversushost
diseas
intens
condit
regimen
allograft
cmv
infect
pneumon
also
develop
major
lung
transplant
recipi
seroneg
infect
develop
singlelung
recipi
diseas
especi
mark
transplant
lung
patient
cmv
pneumon
may
factor
develop
bronchiol
obliteran
cmv
also
primari
pathogen
person
aid
although
often
encount
conjunct
pulmonari
pathogen
see
chapter
characterist
patient
cmv
pneumonia
sustain
fever
nonproduct
cough
dyspnea
rale
tachypnea
often
present
mark
hypoxemia
indic
lifethreaten
infect
pneumon
may
accompani
mild
neutropenia
thrombocytopenia
elev
liver
enzym
may
help
differenti
diagnosi
recent
cmv
reactiv
demonstr
play
role
critic
ill
previous
immunocompet
patient
critic
ill
evid
suggest
greater
popul
high
densiti
lead
infect
earli
age
addit
transmiss
sexual
intercours
passag
contamin
birth
canal
ingest
breast
milk
cmv
infect
acquir
transfus
blood
product
transplant
organ
season
pattern
cmv
infect
observ
human
fibroblast
cell
cultur
cmv
produc
slowli
progress
lytic
infect
infect
cell
contain
larg
irregular
basophil
intranuclear
inclus
also
eosinophil
inclus
paranuclear
area
intranuclear
inclus
hallmark
cmv
infect
found
cell
number
organ
includ
kidney
liver
gi
tract
well
lung
fig
lung
fibroblast
epitheli
cell
endotheli
cell
smooth
muscl
cell
target
cmv
infect
immunocompet
person
infect
subclin
symptom
aris
typic
manifest
acut
pharyng
featur
similar
mono
marrowstem
cell
transplant
recipi
combin
ganciclovir
therapi
intraven
cmv
immun
globulin
reduc
mortal
approxim
lower
patient
effect
immun
globulin
situat
may
mostli
amelior
graftversushost
diseas
whether
combin
therapi
requir
solid
organ
transplant
recipi
cmv
pneumonia
uncertain
cidofovir
foscarnet
antivir
drug
activ
cmv
use
success
treat
cmv
retin
effect
treat
cmv
pneumonia
establish
avail
cmv
antivir
potenti
seriou
side
effect
requir
close
monitor
guidelin
reduc
risk
cmv
diseas
stem
cell
transplant
recipi
publish
transplant
candid
screen
evid
cmv
immun
cmvseroneg
recipi
allogen
stem
cell
transplant
cmvseroneg
donor
receiv
leukocytereduc
cmvseroneg
rbc
andor
leukocytereduc
platelet
mismatch
solid
organ
transplant
recipi
seroneg
recipi
seroposit
donor
posttranspl
prophylaxi
oral
ganciclovir
prodrug
valganciclovir
significantli
reduc
risk
cmv
diseas
although
lateonset
diseas
still
happen
anoth
strategi
preemptiv
therapi
ganciclovir
anoth
anticmv
agent
screen
detect
infect
clinic
detect
diseas
develop
strategi
requir
use
rapid
sensit
specif
laboratori
test
diagnosi
vaccin
avail
prevent
cmv
infect
diseas
although
sever
strategi
activ
pursu
includ
live
attenu
inactiv
subunit
vaccin
hantavirus
member
bunyaviru
famili
includ
number
genet
divers
virus
hantaviru
respons
outbreak
sever
pulmonari
diseas
southwestern
unit
state
sin
nombr
viru
roughli
spheric
mean
diamet
nm
virion
contain
dens
envelop
surround
fine
surfac
project
filament
nucleocapsid
present
within
virion
genom
consist
negativesens
singlestrand
rna
arrang
three
physic
discret
gene
segment
smallest
segment
encod
nucleoprotein
middles
segment
two
envelop
glycoprotein
largest
l
put
polymeras
protein
viral
entri
cell
mediat
varieti
cell
surfac
integrin
may
relat
pattern
pathogen
viru
genom
segment
genet
reassort
dualli
infect
cell
common
believ
new
pathogen
strain
aris
mechan
hantaviru
pulmonari
syndrom
hp
zoonosi
human
experi
sever
often
fatal
diseas
individu
hantaviru
strain
appear
associ
specif
rodent
host
eg
sin
nombr
viru
deer
mous
bayou
viru
rice
rat
black
creek
transient
vulner
period
immunoparalysi
make
reactiv
exogen
infect
cmv
like
patient
cmv
viremia
found
associ
prolong
hospit
death
current
unclear
whether
cmv
prophylaxi
would
benefici
set
cytomegaloviru
pneumonia
differenti
diagnosi
immunosuppress
patient
unexplain
lower
respiratori
complaint
pulmonari
opac
howev
clinic
assess
patient
suspect
cmv
pneumonia
complic
often
simultan
pulmonari
infect
microb
clinic
featur
radiograph
appear
cmv
pneumonia
suffici
characterist
permit
accur
etiolog
diagnosi
addit
noninfecti
pulmonari
condit
also
common
popul
risk
cmv
pneumon
includ
pulmonari
malign
hemorrhag
posttranspl
lymphoprolif
disord
see
efig
chest
radiograph
chang
see
efig
usual
bilater
diffus
focal
hazi
involv
mid
lower
lung
field
miliari
interstiti
radiograph
pattern
describ
patient
miliari
pattern
may
sudden
onset
tachypnea
sever
respiratori
distress
hypoxemia
result
rapidli
fatal
cours
wherea
patient
interstiti
pattern
diseas
often
insidi
onset
pneumonia
slowli
progress
hypoxemia
patient
pulmonari
opac
may
initi
local
bilater
spread
day
week
often
perihilar
distribut
opac
suggest
pulmonari
edema
common
chest
ct
scan
find
includ
small
nodul
see
efig
consolid
see
efig
groundglass
attenu
see
efig
patient
possibl
cmv
pneumonia
prefer
approach
diagnosi
quantit
pcr
serum
bronchoalveolar
lavag
bal
fluid
cultur
patholog
examin
specimen
obtain
bal
transbronchi
biopsi
may
also
diagnost
although
specimen
less
suitabl
make
manag
decis
acut
ill
patient
detect
viru
respiratori
secret
urin
blood
establish
certainti
cmv
respons
particular
clinic
syndrom
particularli
true
patient
aid
detect
cmv
bal
often
associ
pulmonari
patholog
howev
transplant
recipi
presenc
cmv
blood
increas
risk
subsequ
develop
cmv
pneumonia
use
guid
preemptiv
therapi
serolog
test
role
diagnosi
acut
infect
use
determin
serolog
statu
donor
recipi
transplant
cmv
pneumon
establish
particularli
allogen
bone
marrow
transplant
patient
poor
outcom
common
ganciclovir
highli
activ
cmv
vitro
monotherapi
effect
pneumon
bone
period
sever
day
patient
present
mild
nonproduct
cough
progress
dyspnea
result
leakag
highprotein
edema
fluid
alveoli
physic
examin
patient
febril
tachypnea
tachycardia
mild
hypotens
examin
chest
may
reveal
fine
crackl
otherwis
unremark
laboratori
studi
gener
reveal
hemoconcentr
mild
thrombocytopenia
mildli
elev
liver
function
test
triad
thrombocytopenia
left
shift
circul
myeloblast
circul
immunoblast
highli
suggest
hp
multivari
analysi
identifi
dizzi
nausea
absenc
cough
clinic
symptom
predict
hp
well
thrombocytopenia
elev
hematocrit
decreas
serum
bicarbon
featur
help
distinguish
hp
caus
acut
respiratori
distress
pneumococc
pneumonia
influenza
mild
renal
abnorm
may
detect
unlik
situat
anoth
hantavir
ill
hemorrhag
fever
renal
syndrom
progress
renal
failur
renal
dysfunct
may
common
hp
associ
bayou
hantaviru
pleural
effus
present
case
earli
cours
hp
effus
transud
later
develop
higher
fluid
protein
content
sever
case
protein
characterist
plasma
cardiopulmonari
manifest
sever
case
includ
shock
state
low
cardiac
index
low
stroke
volum
index
high
system
vascular
resist
progress
associ
worsen
cardiac
dysfunct
develop
lactic
acidosi
patient
surviv
exert
dyspnea
reduc
expiratori
flow
common
earli
convalesc
resolv
patient
howev
patient
manifest
longterm
pulmonari
cognit
dysfunct
chest
radiograph
typic
pulmonari
edema
without
consolid
absenc
immunodefici
patient
univers
detect
serum
immunoglobulin
igm
igg
antibodi
time
admiss
serolog
techniqu
mainstay
diagnosi
lowpreval
area
posit
igm
diagnost
viru
also
detect
blood
revers
transcriptas
polymeras
chain
reaction
rtpcr
first
day
ill
contrast
hantavirus
difficult
isol
clinic
materi
cell
cultur
grow
slowli
isol
viru
tissu
labori
time
consum
must
undertaken
suitabl
contain
facil
use
diagnosi
treatment
support
requir
care
manag
fluid
statu
maintain
perfus
without
exacerb
pulmonari
edema
suggest
highdos
steroid
therapi
may
use
pathogenesi
diseas
potenti
util
steroid
system
capillari
leak
syndrom
sever
case
extracorpor
membran
oxygen
may
benefici
broadspectrum
antivir
agent
ribavirin
activ
hantaviru
vitro
demonstr
effect
hantavirusinduc
hemorrhag
fever
renal
canal
viru
bccv
cotton
rat
new
york
viru
whitefoot
mous
rodent
host
experi
prolong
asymptomat
infect
featur
associ
mainten
virus
rodent
popul
rodenttorod
transmiss
unclear
serolog
studi
suggest
hantavir
infect
feral
rodent
widespread
throughout
north
america
transmiss
human
presum
result
contact
infect
rodent
excreta
hantavirus
stabl
persist
environ
day
without
loss
viabil
risk
factor
acquisit
hp
includ
high
densiti
rodent
household
clean
contamin
environ
agricultur
activ
form
occup
exposur
rodent
drop
four
corner
region
southwestern
unit
state
el
oscil
event
link
increas
rainfal
high
rodent
popul
densiti
increas
number
case
hp
persontoperson
transmiss
seen
north
american
outbreak
contrast
recent
outbreak
hp
south
america
suggest
certain
circumst
persontoperson
transmiss
take
place
featur
appear
uniqu
particular
hantaviru
implic
outbreak
and
viru
major
compon
outbreak
current
approxim
case
hp
per
year
report
unit
state
case
fatal
rate
infect
sin
nombr
viru
agent
hp
rel
long
incub
period
median
day
rang
day
antibodi
cellular
respons
human
usual
detect
time
present
neutral
antibodi
direct
surfac
glycoprotein
lower
titer
present
correl
greater
diseas
sever
viremia
detect
present
declin
promptli
resolut
fever
patholog
find
fatal
case
includ
pleural
effus
alveolar
edema
fibrin
interstiti
mononuclear
cell
infiltr
littl
necrosi
neutrophil
infiltr
find
felt
consist
capillari
leak
syndrom
subsequ
noncardiogen
pulmonari
edema
immunopatholog
respons
play
major
role
hp
infect
human
sin
nombr
viru
hantavirus
result
widespread
express
viral
antigen
endotheli
cell
pulmonari
cardiac
tissu
cell
respons
peak
time
maxim
clinic
symptom
implic
respons
pathogenesi
diseas
myocardi
depress
also
ascrib
induct
nitric
oxid
local
secret
cytokin
respons
infect
anoth
pathogen
mechan
may
antagon
host
innat
immun
respons
hantaviru
tail
present
hp
begin
prodrom
fever
chill
myalgia
occasion
accompani
abdomin
discomfort
gi
symptom
gener
malais
upper
respiratori
symptom
usual
absent
variabl
latent
infect
establish
sensori
nerv
ganglia
follow
lifelong
recurr
viru
shed
often
lesion
skin
mucou
membran
involv
dermatom
cellular
immun
primari
import
control
hsv
infect
studi
patient
aid
sever
mucocutan
hsv
indic
cell
contribut
control
viral
replic
spread
acut
gingivostomat
pharyng
herpet
diseas
oral
caviti
pharynx
common
overt
manifest
primari
infect
scatter
cluster
vesicl
ulcer
variou
size
mm
locat
buccal
mucosa
tongu
gingiva
floor
mouth
individu
lesion
usual
appear
shallow
whitebas
ulcer
surround
thin
rim
erythema
pain
promin
involv
area
mouth
pharynx
region
node
tender
enlarg
particularli
pharyng
fever
malais
reduc
oral
intak
may
add
overal
sever
ill
last
week
chronic
ulcer
pharyng
laryngotrach
immunocompromis
patient
includ
aid
primari
recurr
hsv
infect
may
manifest
chronic
eros
process
mucou
membran
oral
caviti
upper
airway
characterist
lesion
appear
larg
mm
individu
ulcer
slowli
progress
may
coalesc
present
adjac
site
base
ulcer
white
gray
although
shallow
lesion
usual
pain
may
reduc
oral
intak
herpet
lesion
sometim
present
lip
skin
face
infect
may
spread
esophagu
lower
airway
possibl
facilit
instrument
orotrach
intub
bronchoscopi
result
develop
similar
lesion
site
clinic
featur
herpet
tracheobronch
includ
dyspnea
cough
fever
chill
diaphoresi
chest
pain
wheez
hypotens
hypoxemia
herpet
tracheobronch
also
report
elderli
patient
present
bronchospasm
histori
chronic
lung
diseas
immunosuppress
pneumonia
herp
simplex
viru
caus
pneumonia
neonat
congenit
peripartum
infect
patient
malign
burn
organ
transplant
condit
associ
impair
immun
herp
simplex
pneumonia
report
neonat
third
day
life
associ
promin
hila
central
interstiti
opac
chest
radiographi
associ
find
includ
thrombocytopenia
dissemin
intravascular
coagul
abnorm
liver
function
vesicular
skin
lesion
deterior
antimicrobi
treatment
patholog
find
infant
children
adult
suggest
diseas
may
result
direct
extens
infect
tracheobronchi
tree
lung
result
hematogen
dissemin
viru
mucocutan
lesion
upper
airway
genitourinari
tract
ct
scan
find
includ
multifoc
segment
subsegment
groundglass
opac
syndrom
korea
howev
trial
ribavirin
hp
shown
efficaci
herp
simplex
viru
hsv
type
belong
alphaherpesviru
subfamili
herpesvirus
share
basic
structur
featur
commonli
associ
respiratori
infect
wherea
commonli
associ
genit
infect
two
hsv
type
origin
differenti
neutral
assay
found
differ
number
biolog
biochem
properti
well
infect
either
type
result
product
typespecif
crossreact
antibodi
higher
concentr
antibodi
produc
homolog
type
human
reservoir
virus
primari
infect
infecti
viru
produc
skin
mucou
membran
present
vesicl
fluid
cellular
debri
herpet
ulcer
establish
latenc
nerv
ganglia
viru
intermitt
shed
respiratori
vagin
urethr
secret
absenc
clinic
diseas
asymptomat
respiratori
tract
shed
detect
seroposit
children
adult
spread
mean
transfer
viruscontain
respiratori
secret
vesicl
fluid
cell
debri
condit
close
person
contact
portal
entri
primari
infect
mucou
membran
oropharynx
possibl
eye
viru
deposit
onto
area
burn
abrad
skin
exogen
inocul
autoinocul
viru
also
lead
clinic
lesion
case
aris
sporad
throughout
year
occasion
small
cluster
infect
usual
acquir
childhood
adolesc
epidemiolog
survey
show
preval
antibodi
adult
primari
hsv
infect
mean
incub
period
approxim
week
primari
infect
begin
local
site
viral
replic
parabas
intermedi
epitheli
cell
result
cell
destruct
initi
host
inflammatori
respons
cell
contain
characterist
nuclear
inclus
sometim
multinucl
may
observ
lesion
immunocompet
individu
region
lymph
node
may
involv
primari
infect
diseas
usual
contain
primari
site
innat
antivir
respons
neonat
other
defici
impair
immun
system
local
infect
may
follow
virem
spread
multipl
organ
includ
skin
liver
brain
adren
lung
diseas
may
also
dissemin
individu
follow
reactiv
latent
infect
viscer
infect
character
highli
destruct
coagul
necrosi
involv
site
seri
fatal
case
hsv
pneumonia
inflammatori
infiltr
parenchym
necrosi
hemorrhag
found
autopsi
patient
associ
herpet
laryngotrach
necrot
lesion
area
hsv
pneumonia
depend
obtain
sampl
involv
lung
viral
cultur
test
hsv
antigen
nucleic
acid
limit
experi
lung
biopsi
patient
hsv
pneumonia
suggest
obtain
adequ
sampl
cultur
histolog
examin
may
problem
possibl
gener
biopsi
specimen
obtain
vaccin
proven
valu
current
avail
primari
hsv
gingivostomat
immunocompet
person
respond
oral
acyclovir
treatment
specif
therapi
herp
simplex
pneumonia
evalu
control
trial
clinician
would
use
intraven
acyclovir
immunosuppress
patient
chronic
mucocutan
hsv
infect
includ
pharyng
laryngotrach
prompt
treatment
acyclovir
recommend
control
local
infect
prevent
possibl
dissemin
lung
valacyclovir
valin
ester
prodrug
acyclovir
famciclovir
prodrug
penciclovir
oral
administ
drug
also
effect
mucocutan
hsv
antivir
suscept
test
consid
patient
seriou
hsv
infect
respond
initi
treatment
oral
valacyclovir
intraven
acyclovir
foscarnet
probabl
best
avail
altern
therapi
prophylact
intraven
oral
acyclovir
regimen
shown
effect
prevent
recurr
mucocutan
hsv
infect
seroposit
patient
undergo
intens
period
immunosuppress
bone
marrow
transplant
recipi
patient
receiv
combin
chemotherapi
leukemia
influenza
virus
belong
famili
orthomyxovirida
classifi
three
distinct
type
influenza
influenza
b
influenza
c
viru
three
virus
share
presenc
host
cellderiv
envelop
envelop
glycoprotein
import
entri
egress
cell
segment
negativesens
singlestrand
rna
genom
standard
nomenclatur
influenza
virus
includ
influenza
type
place
initi
isol
strain
design
year
isol
exampl
influenza
viru
isol
patient
puerto
rico
given
strain
design
apuerto
envelop
glycoprotein
hemagglutinin
ha
neuraminidas
na
ha
mediat
bind
viru
sialic
also
known
neuramin
acid
residu
host
cell
glycoprotein
glycolipid
essenti
viral
entri
na
cleav
termin
sialic
acid
neuramin
acid
residu
host
cell
molecul
therebi
releas
new
viral
particl
cell
replic
least
highli
diverg
antigen
distinct
least
distinct
na
describ
influenza
virus
influenza
virus
therefor
divid
subtyp
basi
hemagglutinin
h
neuraminidas
n
eg
infect
influenza
viru
result
longliv
resist
reinfect
homolog
viru
infect
induc
system
local
antibodi
well
cellular
distinct
one
studi
one
half
patient
concomit
pulmonari
infect
microorgan
includ
bacteri
candid
aspergillu
speci
cytomegaloviru
histolog
evid
herpet
esophag
present
patient
herp
pneumonia
esophag
examin
perform
case
nosocomi
acquir
herp
simplex
viru
infect
lower
airway
also
found
associ
ard
relationship
hsv
infect
ard
unclear
presenc
hsv
lower
respiratori
tract
associ
need
prolong
respiratori
support
increas
late
mortal
isol
hsv
lower
respiratori
tract
secret
also
common
mechan
ventil
patient
may
associ
poor
outcom
although
unclear
whether
repres
reactiv
consequ
sever
ill
whether
viru
play
direct
role
mortal
clinic
featur
herpet
gingivostomat
suffici
characterist
permit
accur
diagnosi
case
condit
similar
oral
lesion
limit
includ
herpangina
aphthou
stomat
stevenjohnson
syndrom
enanthem
result
infect
drug
sensit
herpangina
lesion
smaller
mm
often
vesicular
usual
local
soft
palat
ulcer
aphthou
stomat
rel
deep
circumscrib
aphthosi
character
period
recurr
wherea
acut
herpet
gingivostomat
pharyng
limit
singl
occurr
herpet
pharyng
exud
must
distinguish
pharyng
due
streptococcu
pyogen
adenoviru
epsteinbarr
viru
diphtheria
diagnosi
acut
herpet
diseas
oropharynx
confirm
examin
giemsaor
wrightstain
smear
scrape
base
fresh
lesion
tzanck
test
cultur
scrape
swab
specimen
techniqu
rapid
detect
viral
antigen
dna
wide
avail
chronic
ulcer
pharyng
due
hsv
characterist
clinic
appear
highli
suggest
diagnosi
white
color
lesion
may
lead
confus
candidiasi
lesion
thrush
easili
remov
plaqu
ulcer
thrush
chronic
herpet
pharyng
may
coexist
patient
lesion
aphthou
stomat
characterist
found
back
oropharynx
rel
small
mm
fix
diamet
diagnosi
herpet
laryngotrach
may
difficult
inaccess
lesion
diseas
suspect
immunocompromis
patient
herpet
lesion
mouth
upper
airway
skin
face
especi
endotrach
intub
perform
patient
bronchoscop
examin
indic
sampl
suspect
area
cytolog
viral
cultur
diagnosi
hsv
pneumonia
suspect
immunocompromis
patient
unexplain
pulmonari
opac
especi
presenc
herpet
laryngotrach
herpet
lesion
mucocutan
site
includ
genit
area
definit
diagnosi
time
perhap
reason
older
adult
rel
spare
pandem
diseas
affect
mainli
children
adolesc
adult
younger
although
circul
multipl
antigen
subtyp
confin
influenza
virus
influenza
b
virus
undergo
signific
antigen
variat
well
current
two
antigen
distinct
lineag
influenza
b
cocircul
design
yamagata
victoria
lineag
antibodi
virus
one
lineag
provid
substanti
protect
recent
influenza
vaccin
includ
exampl
see
later
infect
influenza
viru
human
gener
limit
respiratori
tract
inocul
incub
period
thought
hour
depend
part
inoculum
dose
viru
shed
maxim
onset
ill
may
continu
day
longer
children
immunocompromis
patient
especi
recipi
solid
organ
hematopoiet
stem
cell
transplant
viral
shed
prolong
week
month
bronchoscopi
individu
influenza
typic
reveal
diffus
inflamm
larynx
trachea
bronchi
well
rang
histolog
find
vacuol
columnar
cell
cell
loss
extens
desquam
ciliat
columnar
epithelium
basal
layer
cell
gener
tissu
respons
becom
promin
one
move
distal
airway
recoveri
associ
rapid
regener
epitheli
cell
layer
pseudometaplasia
fatal
influenza
pneumonia
exhibit
diffus
alveolar
damag
hyalin
membran
line
alveoli
alveolar
air
space
contain
edema
fluid
strand
fibrin
desquam
epitheli
cell
inflammatori
cell
fig
abnorm
pulmonari
function
frequent
demonstr
otherwis
healthi
nonasthmat
young
adult
uncompl
nonpneumon
acut
influenza
demonstr
defect
includ
diminish
forc
expiratori
flow
rate
increas
total
pulmonari
resist
decreas
densitydepend
forc
expiratori
flow
rate
consist
gener
increas
resist
airway
less
mm
diamet
well
increas
respons
bronchoprovoc
addit
abnorm
seen
carbon
monoxid
diffus
capac
alveolararteri
oxygen
differ
pulmonari
function
defect
persist
week
clinic
recoveri
influenza
asthmat
patient
chronic
obstruct
diseas
influenza
may
result
acut
declin
forc
vital
capac
fev
individu
acut
influenza
may
suscept
bronchoconstrict
air
pollut
nitrat
typic
uncompl
influenza
often
begin
abrupt
onset
symptom
incub
period
day
system
symptom
includ
feverish
chilli
frank
shake
chill
headach
myalgia
malais
anorexia
typic
respiratori
symptom
includ
dri
cough
sever
pharyng
pain
nasal
obstruct
discharg
elderli
individu
may
simpli
present
respons
play
role
recoveri
infect
resist
reinfect
influenza
viru
infect
acquir
transfer
viruscontain
respiratori
secret
small
particl
aerosol
droplet
probabl
play
role
transmiss
infect
control
purpos
influenza
gener
consid
transmit
droplet
temper
climat
either
hemispher
epidem
seen
almost
exclus
winter
month
gener
octob
april
northern
hemispher
may
septemb
southern
hemispher
wherea
tropic
influenza
may
seen
throughout
year
influenza
epidem
regularli
associ
morbid
mortal
usual
express
form
excess
rate
pneumonia
influenzaassoci
hospit
death
mani
death
annual
unit
state
attack
rate
gener
highest
young
wherea
mortal
gener
highest
elderli
excess
morbid
mortal
particularli
high
medic
condit
includ
pulmonari
condit
asthma
copd
rate
influenzarel
hospit
particularli
high
healthi
children
younger
rate
approach
older
children
highrisk
condit
high
frequenc
antigen
variat
uniqu
featur
influenza
viru
help
explain
viru
continu
caus
epidem
diseas
antigen
variat
princip
involv
two
extern
glycoprotein
viru
ha
na
refer
antigen
drift
antigen
shift
depend
whether
variat
small
great
antigen
drift
refer
rel
minor
antigen
chang
result
amino
acid
chang
one
five
identifi
major
antigen
site
ha
molecul
antigen
shift
refer
complet
replac
ha
na
novel
ha
na
virus
new
virus
popul
specif
immun
new
viru
introduc
popul
sever
worldwid
epidem
pandem
influenza
result
influenza
pandem
centuri
includ
pandem
pandem
pandem
extens
surveil
sequenc
inform
suggest
new
ha
na
gene
introduc
virus
circul
human
resid
popul
influenza
virus
bird
sinc
sporad
outbreak
influenza
human
caus
direct
transmiss
avian
virus
bird
human
report
although
sustain
humantohuman
transmiss
seen
avian
subtyp
continu
pose
potenti
pandem
threat
spring
novel
viru
contain
gene
virus
swine
avian
human
origin
emerg
importantli
ha
gene
viru
deriv
swine
influenza
viru
although
still
viru
novel
pandem
antigen
distinct
human
virus
circul
sinc
instead
ha
close
relat
human
virus
earli
centuri
introduc
pig
approxim
undergon
signific
antigen
evolut
anim
sinc
bilater
abnorm
fig
efig
sometim
suggest
acut
lung
injuri
pattern
ard
efig
swineorigin
influenza
infect
rel
nonspecif
appear
rang
normal
nearli
normal
chest
radiographi
present
multifoc
bilater
opac
resembl
multifoc
pneumonia
efig
noninfecti
acut
lung
injuri
pattern
chest
ct
often
show
multifoc
area
groundglass
opac
consolid
may
show
peripher
distribut
resembl
organ
pneumonia
fever
lassitud
confus
without
characterist
respiratori
complaint
may
wide
rang
symptom
presenc
fever
plu
either
sore
throat
cough
predict
posit
cultur
result
influenza
adult
syndrom
primari
influenza
viral
pneumonia
first
well
document
outbreak
ill
begin
typic
onset
influenza
follow
rapid
progress
fever
cough
dyspnea
cyanosi
physic
examin
thorac
imag
studi
reveal
fig
report
sensit
test
comparison
cell
cultur
nucleic
acid
amplif
vari
depend
natur
sampl
test
viral
strain
gener
sensit
adult
elderli
patient
tend
lower
report
young
children
shed
much
larger
quantiti
viru
higher
concentr
antigen
sampl
similarli
sensit
like
higher
earli
cours
ill
viral
shed
maxim
molecular
diagnost
techniqu
recent
emerg
diagnost
modal
choic
laboratori
realtim
rtpcr
method
develop
licens
discuss
greater
detail
chapter
mani
test
design
detect
multipl
respiratori
pathogen
simultan
lead
grow
recognit
role
respiratori
virus
coinfect
divers
respiratori
infect
case
influenza
otherwis
healthi
individu
typic
symptom
cours
recogn
influenza
epidem
need
specif
viral
confirm
howev
diagnost
test
use
result
test
influenc
subsequ
clinic
manag
use
antivir
agent
need
antibacteri
drug
use
infect
control
viru
also
isol
readili
nasal
swab
specimen
nasal
aspir
combin
nose
throat
swab
sputum
endotrach
aspir
specimen
posit
influenza
cultur
detect
within
day
inocul
efig
although
pattern
includ
small
nodul
efig
b
groundglass
opac
associ
linear
reticular
abnorm
without
clear
zonal
distribut
efig
lobar
consolid
efig
may
observ
gram
stain
sputum
fail
reveal
signific
bacteria
bacteri
cultur
yield
spars
growth
normal
flora
wherea
viral
cultur
yield
high
titer
influenza
viru
patient
respond
antibacteri
drug
mortal
high
secondari
bacteri
pneumonia
import
complic
influenza
fig
efig
classic
descript
influenza
ill
follow
period
improv
usual
last
day
recrudesc
fever
associ
symptom
sign
bacteri
pneumonia
cough
sputum
product
area
consolid
detect
physic
examin
chest
radiographi
common
bacteria
implic
streptococcu
pneumonia
significantli
increas
frequenc
staphylococcu
aureu
includ
methicillinresist
staphylococcu
mrsa
patient
may
present
mix
viral
bacteri
pneumonia
bacteri
superinfect
influenza
postul
major
caus
death
pandem
patient
wide
rang
preexist
condit
well
recogn
higher
risk
develop
pneumonia
complic
influenza
lead
hospit
death
tabl
recent
year
new
condit
lead
increas
risk
recogn
includ
presenc
neuromuscular
condit
compromis
respir
pandem
presenc
obes
addit
pandem
reemphas
known
increas
risk
hospit
death
women
stage
pregnanc
immedi
postpartum
period
diagnosi
immunolog
detect
influenza
antigen
respiratori
sampl
use
rapid
diagnosi
larg
number
test
commerci
avail
see
chapter
although
vaccin
viru
recov
vaccin
individu
particularli
children
sever
day
follow
vaccin
transmiss
extrem
unusu
live
vaccin
administ
safe
health
care
worker
except
care
immunosuppress
individu
requir
barrier
precaut
random
control
comparison
efficaci
inactiv
live
attenu
vaccin
children
consist
shown
live
vaccin
provid
superior
efficaci
popul
approxim
lower
cumul
incid
influenza
receiv
live
vaccin
similar
comparison
adult
suggest
slightli
superior
efficaci
inactiv
vaccin
larg
cohort
studi
also
consist
interpret
inactiv
vaccin
slightli
better
efficaci
live
vaccin
adult
particularli
receiv
vaccin
previou
year
previou
strategi
prevent
influenza
unit
state
countri
focus
target
vaccin
person
higher
risk
influenzarel
complic
see
tabl
individu
close
contact
highrisk
individu
recommend
complex
way
difficult
implement
lead
lower
desir
vaccin
uptak
addit
recogn
univers
vaccin
strategi
particularli
children
might
abl
impact
spread
influenza
commun
current
unit
state
mani
countri
adopt
univers
vaccin
strategi
annual
vaccin
member
popul
cours
includ
health
care
provid
institut
adopt
polici
mandatori
vaccin
individu
contact
patient
antibodi
respons
influenza
viru
whether
induc
vaccin
natur
infect
predominantli
direct
globular
head
domain
ha
protein
involv
bind
host
cell
domain
ha
mutat
frequent
amino
acid
substitut
domain
allow
new
viral
variant
escap
recognit
antibodi
develop
respons
origin
viru
thu
new
antigen
variant
virus
emerg
regularli
necessit
develop
administr
new
influenza
vaccin
year
costli
logist
complex
requir
distinct
influenza
vaccin
year
stimul
effort
develop
vaccin
target
conserv
domain
influenza
viru
hemagglutinin
rather
variabl
globular
head
domain
although
effort
reveal
evid
broadli
neutral
antibodi
produc
certain
subject
clear
strategi
product
vaccin
induc
broadli
neutral
antibodi
yet
emerg
antivir
two
class
antivir
agent
current
avail
treatment
prevent
influenza
inhibitor
amantadin
rimantadin
adamantan
neuraminidas
inhibitor
nai
oseltamivir
zanamivir
protein
locat
viral
envelop
function
proton
channel
essenti
viral
escap
host
cell
cytoplasm
viral
replic
take
place
adamantan
specif
block
ion
channel
function
influenza
protein
activ
influenza
vaccin
two
type
vaccin
avail
prevent
influenza
inactiv
vaccin
consist
partial
purifi
ha
na
prepar
deriv
virion
produc
egg
cell
cultur
one
case
purifi
recombin
ha
produc
insect
cell
current
vaccin
contain
one
exampl
one
exampl
either
one
lineag
influenza
b
inactiv
vaccin
administ
intramuscularli
intraderm
primarili
design
induc
system
antibodi
although
also
induc
cellular
immun
respons
may
associ
protect
inactiv
vaccin
well
toler
age
group
although
hypersensit
hen
egg
rel
contraind
use
eggproduc
vaccin
gener
person
eat
egg
eggcontain
product
vaccin
safe
necessari
individu
anaphylaxi
desensit
safe
vaccin
vaccin
free
egg
product
use
increas
hemagglutinationinhibit
antibodi
seen
healthi
adult
recipi
vaccin
singl
dose
vaccin
requir
individu
previous
vaccin
experienc
prior
infect
relat
subtyp
twodos
schedul
requir
unprim
individu
includ
children
age
previous
vaccin
vaccin
first
time
singl
dose
previou
season
diminish
respons
diminish
efficaci
seen
elderli
immunocompromis
popul
protect
efficaci
inactiv
influenza
vaccin
estim
rang
healthi
adult
good
antigen
match
vaccin
epidem
virus
prospect
trial
protect
efficaci
conduct
highrisk
popul
one
placebocontrol
prospect
trial
inactiv
vaccin
approxim
effect
prevent
influenza
among
adult
older
older
howev
studi
use
serolog
definit
influenza
infect
possibl
bias
result
favor
vaccin
efficaci
observ
studi
suggest
practic
effect
inactiv
vaccin
prevent
acut
respiratori
ill
due
influenza
rang
even
lower
effect
older
adult
season
antigen
mismatch
attempt
improv
effect
inactiv
vaccin
includ
use
higher
dose
adjuv
live
attenu
vaccin
administ
intranas
induc
limit
asymptomat
infect
upper
respiratori
tract
induc
varieti
immun
respons
design
mimic
protect
immun
induc
natur
infect
vaccin
well
toler
highli
effect
children
associ
increas
frequenc
wheez
children
younger
year
age
live
vaccin
protect
adult
well
result
decreas
laboratoryconfirm
influenza
challeng
studi
reduc
frequenc
influenzalik
ill
field
although
vaccin
well
toler
elderli
chronic
lung
diseas
immun
respons
less
frequent
older
recipi
vaccin
licens
use
older
relat
complic
reduct
use
antibacteri
hospit
oseltamivir
current
licens
use
children
younger
year
age
administr
oseltamivir
liquid
dose
mgkg
children
month
age
mgkg
children
month
age
twice
daili
day
reach
target
rang
earlier
studi
show
well
toler
result
reduct
durat
symptom
children
influenza
nai
also
use
success
season
contact
prophylaxi
initi
placebocontrol
trial
nai
therapi
conduct
primarili
otherwis
healthi
adult
captur
substanti
number
influenza
complic
howev
pool
analys
studi
earli
therapi
zanamivir
oseltamivir
demonstr
signific
reduct
rate
influenza
complic
treat
individu
subsequ
experi
emerg
epidem
viru
also
suggest
benefici
effect
earli
therapi
complic
includ
observ
hospit
patient
surveil
data
suggest
therapi
late
day
improv
surviv
hospit
patient
surveil
data
also
suggest
treat
children
lower
rate
complic
mutat
within
catalyt
framework
na
abolish
bind
drug
describ
depend
locat
mutat
virus
may
specif
resist
one
inhibitor
resist
mutat
na
may
also
associ
alter
characterist
enzym
significantli
reduc
activ
drugresist
virus
commonli
isol
treat
children
viral
fit
appear
less
compromis
oseltamivir
resist
mutat
neuraminidas
resist
common
among
season
virus
pandem
current
major
season
influenza
virus
suscept
drug
resist
sporad
report
import
continu
monitor
suscept
pattern
although
benefit
antivir
therapi
initi
demonstr
shorten
ill
durat
healthi
adult
uncompl
influenza
gener
consid
prioriti
target
group
antivir
therapi
current
recommend
includ
use
antivir
individu
risk
sever
influenza
individu
sever
diseas
requir
hospit
treatment
start
earli
possibl
even
delay
therapi
benefit
hospit
patient
treatment
patient
requir
mechan
ventil
challeng
administr
oseltamivir
nasogastr
tube
effect
intraven
prepar
zanamivir
experiment
nai
peramivir
avail
compassion
use
protocol
measl
viru
classifi
morbilliviru
genu
paramyxovirida
famili
structur
similar
parainfluenza
viru
rsv
surfac
glycoprotein
includ
hemagglutinin
respons
attach
cell
fusion
f
protein
respons
cell
membran
fusion
viru
b
virus
resist
drug
emerg
readili
treat
individu
particularli
children
may
prolong
shed
resist
virus
immunocompromis
patient
even
therapi
termin
reason
remain
unclear
first
decad
centuri
seen
emerg
spread
adamantaneresist
influenza
virus
virus
also
uniformli
resist
therefor
adamantan
drug
util
current
influenza
virus
might
use
suscept
strain
emerg
futur
nai
potent
inhibitor
influenza
viru
vitro
vivo
neuraminidas
activ
essenti
viral
releas
necessari
step
viral
spread
cell
influenza
b
virus
somewhat
less
sensit
influenza
virus
well
within
clinic
achiev
concentr
avian
virus
nine
known
neuraminidas
subtyp
also
sensit
although
zanamivir
oseltamivir
ident
mechan
action
similar
profil
antivir
activ
differ
pharmacolog
properti
zanamivir
oral
bioavail
administ
dri
powder
oral
inhal
use
socal
diskhal
devic
oseltamivir
phosphat
oral
bioavail
ethyl
ester
prodrug
rapidli
absorb
gi
tract
convert
liver
hepat
esteras
activ
metabolit
oseltamivir
carboxyl
metabolit
excret
unchang
urin
tubular
secret
serum
halflif
hour
major
advers
effect
report
oseltamivir
gi
upset
recipi
probabl
due
irrit
caus
rapid
releas
drug
stomach
rate
nausea
substanti
reduc
drug
taken
food
advers
effect
report
zanamivir
essenti
rate
placebo
recipi
howev
postmarket
surveil
found
inhal
zanamivir
may
uncommonli
associ
bronchospasm
influenza
patient
particularli
underli
airway
diseas
acut
bronchospasm
sometim
sever
fatal
dose
oseltamivir
reduc
mg
daili
individu
renal
impair
ie
creatinin
clearanc
mlmin
mg
everi
day
prophylact
treatment
data
avail
regard
use
drug
individu
signific
level
renal
impair
likewis
inform
avail
regard
use
oseltamivir
individu
hepat
impair
clinic
signific
drug
interact
report
drug
elimin
tubular
secret
probenecid
increas
serum
level
activ
metabolit
approxim
twofold
howev
dosag
adjust
necessari
individu
take
probenecid
coadministr
cimetidin
amoxicillin
acetaminophen
effect
serum
level
oseltamivir
oseltamivir
carboxyl
zanamivir
signific
system
absorpt
recommend
dosag
reduct
nai
effect
treatment
influenza
due
either
influenza
b
viru
administ
within
first
hour
symptom
onset
reduc
durat
ill
earlier
return
work
normal
activ
metaanalysi
result
trial
also
suggest
earli
treatment
may
reduc
frequenc
influenzath
onset
rash
correl
tempor
develop
host
immun
respons
subsequ
termin
viru
shed
skin
rash
develop
agammaglobulinem
patient
measl
wherea
progress
giant
cell
measl
viru
pneumonia
without
rash
may
develop
defici
cellmedi
immun
function
patholog
chang
involv
organ
includ
lymphoid
hyperplasia
mononuclear
cell
infiltr
presenc
multinucl
giant
cell
lower
respiratori
tract
involv
may
associ
destruct
ciliat
respiratori
epithelium
interstiti
pneumonia
epitheli
cell
hyperplasia
syncyti
cell
format
typic
measl
typic
prodrom
measl
last
day
character
fever
malais
anorexia
cough
coryza
conjunct
koplik
spot
erythemat
macular
lesion
central
whiteyellow
gray
puncta
appear
buccal
labial
mucou
membran
toward
end
prodrom
period
maculopapular
erythemat
erupt
begin
face
neck
progress
involv
upper
bodi
trunk
extrem
rash
typic
resolv
day
order
appear
fever
abat
symptom
improv
sever
day
appear
rash
although
persist
cough
common
leukopenia
common
prodrom
earli
exanthemat
stage
measl
pronounc
leukopenia
associ
poor
prognosi
develop
neutrophil
leukocytosi
suggest
possibl
bacteri
superinfect
complic
lower
respiratori
tract
complic
develop
patient
includ
bronchiti
pneumonia
less
often
croup
bronchiol
young
adult
multilobar
reticulonodular
opac
common
radiograph
abnorm
see
efig
absenc
bacteri
superinfect
atyp
measl
pleural
effus
lobar
consolid
uncommon
patient
alter
cellmedi
immun
function
rare
appar
normal
person
infect
wild
measl
viru
caus
lethal
giant
cell
pneumonia
without
rash
sever
virusinduc
pneumonia
recogn
measl
pregnant
women
infect
hiv
hospit
patient
mortal
rate
approxim
oncolog
patient
hivinfect
patient
secondari
bacteri
infect
found
young
adult
measlesrel
pneumonia
symptom
sign
indic
bacteri
infect
usual
begin
day
onset
rash
one
studi
employ
transtrach
aspir
found
rang
bacteri
pathogen
adult
commonli
haemophilu
influenza
neisseria
meningitidi
pneumonia
case
complic
otiti
media
sinus
acut
nonrespiratori
complic
includ
hepat
enceph
kerat
mesenter
aden
well
high
rate
sever
diarrheal
diseas
children
develop
countri
measl
infect
vaccin
may
accompani
convers
tuberculin
skin
reaction
posit
neg
week
measl
may
exacerb
activ
penetr
cell
neuraminidas
cell
surfac
molecul
slam
signal
lymphocyt
activ
molecul
serv
receptor
entri
viru
suscept
cell
addit
complement
regulatori
protein
also
serv
receptor
particularli
vaccin
strain
one
serotyp
wild
measl
viru
recogn
although
minor
antigen
differ
detect
monoclon
antibodi
human
sole
natur
host
measl
viru
measl
found
worldwid
epidem
pattern
vari
depend
popul
densiti
level
acquir
immun
vaccin
use
measl
aros
epidem
month
durat
everi
year
temper
region
except
isol
area
peopl
experienc
infect
year
age
report
case
seen
younger
infect
confer
lifelong
protect
measl
although
asymptomat
reinfect
may
develop
measl
viru
infect
highli
contagi
spread
despit
high
level
acquir
immun
popul
airborn
transmiss
via
smallparticl
aerosol
possibl
spread
fomit
appear
account
high
communic
viru
remain
infecti
smallparticl
aerosol
sever
hour
low
rel
humid
caus
secondari
infect
absenc
facetofac
contact
index
case
incub
period
usual
day
may
longer
adult
patient
infecti
late
prodrom
respiratori
involv
contribut
creation
infecti
aerosol
viru
may
shed
sever
day
onset
rash
normal
host
measlesassoci
mortal
develop
countri
usual
less
approach
case
develop
world
case
fatal
rate
high
area
death
result
respiratori
tract
involv
neurolog
complic
relat
variou
combin
malnutrit
young
age
complic
immunosuppress
induc
measl
viru
infect
respiratori
tract
possibl
conjunctiv
epithelium
portal
entri
initi
site
replic
measl
viru
well
subsequ
target
organ
diseas
express
initi
virem
phase
lead
infect
mononuclear
phagocyt
includ
dendrit
cell
second
phase
viremia
correspond
prodrom
stage
ill
result
dissemin
viru
epitheli
cell
skin
respiratori
tract
gut
bile
duct
bladder
lymphoid
organ
measl
virusinduc
giant
cell
may
present
tonsil
appendix
lymphoid
organ
variou
epitheli
surfac
includ
respiratori
tract
effect
infect
lymphoid
system
includ
leukopenia
immun
suppress
manifest
cutan
anergi
depress
natur
killer
cell
activ
week
rash
onset
mechan
measl
induc
immunosuppress
incomplet
understood
infect
dendrit
cell
suppress
product
thought
play
import
role
mission
vaccin
safe
conclus
shown
associ
autism
recent
outbreak
measl
undervaccin
commun
unit
state
often
introduc
import
case
immigr
travel
human
metapneumovirus
hmpv
pleomorph
particl
short
envelop
project
resembl
paramyxovirus
virus
close
relat
pneumovirus
rsv
human
exampl
differ
absenc
two
nonstructur
protein
slightli
differ
arrang
gene
order
negativesens
singlestrand
rna
genom
basic
virolog
virus
close
resembl
rsv
envelop
glycoprotein
includ
sh
sulfhydryl
f
fusion
g
attach
although
littl
sequenc
homolog
gene
rsv
hmpv
analog
expect
antibodi
f
g
protein
hmpv
would
play
role
protect
reinfect
least
two
major
genet
group
identifi
roughli
correspond
subgroup
b
rsv
sequenti
infect
individu
tend
involv
differ
genogroup
role
cellmedi
immun
infect
larg
unexplor
hmpv
infect
distribut
worldwid
document
outpati
inpati
set
recent
estim
diseas
burden
base
pcr
diagnost
suggest
hmpv
result
hospit
emerg
depart
visit
outpati
visit
per
children
younger
children
younger
month
highest
risk
mani
respiratori
virus
infect
link
day
care
attend
serolog
studi
suggest
essenti
children
infect
age
similar
case
rsv
diseas
also
document
adult
elderli
although
asymptomat
infect
also
common
adult
outbreak
sever
diseas
document
residenti
care
facil
older
adult
sever
diseas
may
also
seen
immunocompromis
subject
hematopoiet
stem
cell
transplant
recipi
see
efig
mode
transmiss
document
like
via
droplet
spread
rsv
clear
season
variat
incid
major
case
appear
winter
month
interest
featur
epidemiolog
virus
children
hmpv
often
coinfect
respiratori
viral
pathogen
especi
rsv
dual
infect
virus
may
result
intens
bronchiol
infant
hmpv
also
detect
mani
case
sar
appear
exacerb
ill
human
metapneumovirus
appear
respons
spectrum
acut
respiratori
ill
rang
mild
asymptomat
infect
sever
bronchiol
pneumon
clinic
pictur
close
resembl
tuberculosi
whether
measl
reactiv
dormant
tuberculosi
unresolv
atyp
measl
unusu
clinic
syndrom
recogn
adolesc
young
adult
receiv
inactiv
measl
vaccin
subsequ
reexpos
wild
viru
ill
begin
abruptli
high
fever
headach
myalgia
vomit
abdomin
pain
nonproduct
cough
respiratori
symptom
includ
dyspnea
coryza
sore
throat
pleurit
chest
pain
common
polymorph
erupt
may
includ
vesicl
petechia
purpura
urticari
lesion
begin
typic
distal
extrem
spread
proxim
day
although
koplik
spot
absent
conjunct
glossiti
strawberri
tongu
describ
pulmonari
abnorm
found
case
acut
respiratori
failur
describ
chest
radiograph
chang
includ
patchi
diffus
dens
lobar
opac
pleural
effus
hilar
lymphadenopathi
residu
nodular
pulmonari
opac
may
persist
year
lead
diagnost
confus
fever
symptom
usual
resolv
week
pulmonari
function
chang
atyp
measl
includ
transient
hypoxemia
significantli
reduc
lung
volum
diagnosi
measl
readili
confirm
immunocompet
patient
detect
measl
virusspecif
igm
elisa
immunodefici
patient
detect
measl
viru
nucleic
acid
amplif
urin
sampl
obtain
throat
nasopharyng
swab
sensit
specif
sampl
sent
us
center
diseas
control
http
wwwcdcgovmeasl
labtoolsrtpcrhtml
measl
viru
may
also
isol
blood
urin
respiratori
secret
prodrom
sever
day
exanthem
appear
isol
viru
clinic
specimen
perform
sever
type
human
monkey
cell
cultur
slow
ineffici
respiratori
conjunctiv
secret
urin
sediment
stain
variou
techniqu
reveal
multinucl
giant
cell
case
immunofluoresc
stain
skin
biopsi
specimen
cell
combin
nasopharyng
throat
swab
sampl
less
often
exfoli
cell
urin
demonstr
measl
viru
antigen
earli
diseas
treatment
measl
involv
support
care
specif
therapi
bacteri
complic
antivir
agent
proven
clinic
valu
aerosol
intraven
ribavirin
immunoglobulin
use
treat
measl
pneumonia
vitamin
therapi
reduc
morbid
mortal
sever
measl
children
patient
suspect
measl
place
respiratori
isol
live
attenu
measl
vaccin
current
use
unit
state
provid
durabl
immun
recipi
recent
outbreak
seen
case
adolesc
adult
recipi
two
dose
measl
vaccin
ill
mild
associ
transinfect
cell
viral
replic
f
glycoprotein
membranefus
activ
respons
viral
penetr
cell
format
multinucl
syncyti
cell
antibodi
hn
f
involv
protect
immun
parainfluenza
virus
worldwid
distribut
almost
person
infect
initi
childhood
parainfluenza
type
viru
may
caus
infect
infanc
wherea
infect
type
virus
appear
prevent
matern
antibodi
usual
aris
later
nation
surveil
demonstr
distinct
season
type
virus
biennial
outbreak
fall
oddnumb
year
contrast
yearli
outbreak
type
viru
take
place
spring
smaller
autumn
outbreak
year
without
type
outbreak
type
virus
detect
much
less
frequent
appear
preval
autumn
type
exhibit
notabl
season
parainfluenza
virus
appear
transmit
person
person
direct
contact
infecti
respiratori
secret
largeparticl
aerosol
incub
period
approxim
day
viru
transmit
readili
famili
outbreak
infect
seen
close
popul
nurseri
day
care
center
hospit
suscept
popul
high
attack
rate
parainfluenza
viru
infect
commonli
type
viru
associ
approxim
croup
case
document
viral
caus
smaller
proport
pneumonia
bronchiol
case
children
incid
croup
lower
respiratori
tract
diseas
due
type
infect
highest
month
year
age
wherea
parainfluenza
type
import
caus
bronchiol
pneumonia
infant
younger
month
reinfect
parainfluenza
virus
common
young
children
may
aris
within
sever
month
recent
populationbas
diseas
burden
estim
suggest
children
younger
experi
parainfluenza
virusrel
hospit
hospit
fever
respiratori
ill
age
group
attribut
parainfluenza
viru
although
viremia
describ
replic
viru
gener
restrict
respiratori
tract
mucosa
quantiti
viru
shed
respiratori
secret
tend
parallel
sever
ill
viru
shed
commonli
continu
period
day
initi
infect
may
last
week
longer
prolong
shed
month
parainfluenza
viru
type
report
appar
normal
host
well
immunodefici
children
patholog
find
fatal
case
typic
viral
pneumonia
includ
peribronchiolar
alveolar
lymphocyt
infiltr
infect
tracheal
epithelium
local
edema
fibrin
exud
contribut
airway
narrow
croup
mechan
account
laryngotrach
local
parainfluenza
virusinduc
diseas
unresolv
virushost
cell
rsv
bronchiol
major
manifest
children
clinic
featur
hospit
children
includ
wheez
hypoxia
varieti
lower
upper
respiratori
tract
syndrom
also
associ
hmpv
infect
includ
croup
pneumon
clinic
featur
distinguish
diseas
caus
hmpv
rsv
although
rsv
may
sever
symptomat
infect
adult
elderli
also
describ
hmpv
infect
young
adult
featur
common
cold
nasal
congest
rhinorrhea
cough
hoars
predomin
frail
elderli
highrisk
adult
lower
rate
hmpv
infect
sever
clinic
symptom
significantli
higher
frequenc
dyspnea
wheez
prolong
ill
elderli
patient
hmpv
infect
hospit
diagnos
copd
bronchiti
pneumonia
hmpv
appear
lead
caus
respiratori
tract
infect
lung
transplant
patient
one
studi
hmpv
commonli
detect
rna
viru
bal
sampl
immunocompromis
patient
rel
littl
known
regard
pathogenesi
diseas
hospit
children
hmpv
level
nasal
secret
rant
report
suppress
level
nasal
increas
immun
respons
elicit
hmpv
similar
rsv
often
vigor
viral
cultur
slow
low
sensit
infect
detect
nucleic
acid
amplif
techniqu
avail
panel
detect
identifi
respiratori
virus
see
chapter
treatment
support
antivir
agent
vaccin
current
licens
treatment
prevent
hmpv
infect
unlik
chang
near
futur
ribavirin
activ
vitro
hmpv
hrsv
data
support
therapeut
efficaci
drug
specif
monoclon
antibodi
avail
clinic
use
although
intraven
immunoglobulin
suggest
possibl
therapeut
agent
immunocompromis
host
parainfluenza
virus
belong
paramyxoviru
genu
paramyxovirida
famili
includ
mump
viru
import
veterinari
pathogen
group
mediums
nm
pleomorph
envelop
virus
nonseg
singlestrand
rna
genom
contain
helic
nucleocapsid
human
parainfluenza
virus
separ
type
type
divid
subtyp
b
basi
antigen
differ
one
envelop
glycoprotein
hn
hemagglutinin
neuraminidas
activ
mediat
adsorpt
viru
host
cell
receptor
entri
host
cell
well
subsequ
releas
new
virion
associ
improv
surviv
bone
marrow
transplant
recipi
combin
aerosol
ribavirin
intraven
immunoglobulin
frequent
use
immunocompromis
patient
direct
evid
efficaci
sialidas
activ
vitro
small
clinic
studi
current
avail
clinic
use
initi
attempt
develop
vaccin
prevent
parainfluenza
virus
involv
use
formalininactiv
viru
howev
vaccin
fail
provid
protect
field
trial
carri
despit
modestli
immunogen
contrast
rsv
vaccin
use
formalininactiv
parainfluenza
vaccin
associ
enhanc
diseas
subsequ
infect
sever
approach
explor
subsequ
includ
use
live
attenu
virus
recombin
subunit
vaccin
clinic
trial
ongo
rsv
classifi
pneumoviru
genu
paramyxovirida
famili
similar
structur
parainfluenza
virus
rsv
pleomorph
nm
envelop
viru
singlestrand
nonseg
rna
genom
surfac
protein
includ
f
protein
respons
fusion
viral
envelop
host
cell
membran
format
syncytium
g
protein
heavili
glycosyl
protein
respons
attach
cell
antibodi
f
g
protein
neutral
rsv
vitro
antibodi
g
prevent
syncytium
format
two
major
antigen
group
design
b
distinguish
primarili
differ
g
glycoprotein
clinic
epidemiolog
import
strain
variat
studi
infect
group
strain
appear
sever
antigen
subgroup
genom
heterogen
recogn
among
circul
rsv
strain
rsv
worldwid
distribut
temper
climat
caus
annual
outbreak
infect
late
fall
winter
spring
epidem
associ
increas
pediatr
hospit
death
due
lower
respiratori
tract
ill
infant
young
children
nearli
children
infect
within
first
year
life
almost
infect
year
age
reinfect
children
adult
quit
common
even
strain
suggest
immun
partial
epidemiolog
factor
relat
seriou
ill
infect
infant
includ
low
socioeconom
statu
crowd
matern
smoke
lack
breast
feed
day
care
center
attend
histori
allerg
diseas
rsv
also
recogn
caus
sever
diseas
older
adult
may
result
greater
total
burden
mortal
elderli
infant
rsv
spread
largeparticl
aerosol
close
person
contact
hand
contamin
infecti
secret
subsequ
selfinocul
eye
nose
rsv
major
nosocomi
pathogen
pediatr
ward
high
attack
rate
outbreak
hospit
transplant
unit
day
care
center
geriatr
home
attack
rate
children
approach
interact
specif
cleavag
f
protein
host
factor
includ
natur
immun
respons
postul
play
contributori
role
pathogenesi
croup
nasopharyng
secret
concentr
parainfluenza
virusspecif
ige
histamin
leukotrien
well
cellular
respons
viral
antigen
higher
patient
wheez
upper
respiratori
tract
ill
alon
primari
infect
usual
symptomat
associ
sever
form
ill
initi
infect
parainfluenza
viru
type
caus
febril
rhiniti
pharyng
laryng
bronchiti
children
depend
serotyp
caus
infect
primari
infect
associ
fever
one
third
children
evid
lower
respiratori
tract
involv
parainfluenza
viru
type
infect
lower
respiratori
diseas
princip
manifest
croup
wherea
type
infect
associ
croup
bronchiol
pneumonia
adult
older
children
reinfect
frequent
asymptomat
symptomat
infect
manifest
common
cold
usual
without
fever
less
often
pharyng
tracheobronch
influenzalik
ill
pneumonia
exacerb
chronic
airway
diseas
describ
follow
parainfluenza
viru
infect
adult
elderli
although
uncommon
parainfluenza
virus
caus
seriou
lower
respiratori
tract
diseas
includ
fatal
pneumonia
without
giant
cell
children
immunodefici
leukemia
pediatr
adult
stem
cell
transplant
recipi
nosocomi
outbreak
immunosuppress
patient
report
upper
respiratori
ill
may
absent
nasopharyng
cultur
neg
bal
often
requir
diagnosi
rapid
diagnosi
parainfluenza
infect
made
detect
viral
antigen
rna
respiratori
secret
obtain
use
throat
nasopharyng
swab
detect
parainfluenza
rna
perform
multiplex
nucleic
acid
amplif
panel
respiratori
virus
see
chapter
may
readili
avail
rapid
antigen
detect
assay
respiratori
secret
contain
viru
time
symptom
onset
viral
cultur
also
sensit
parainfluenza
virus
isol
earli
day
usual
within
day
inocul
cell
cultur
specimen
infant
children
viru
replic
cell
cultur
usual
detect
hemadsorpt
guinea
pig
erythrocyt
immunofluoresc
current
avail
antivir
agent
proven
effect
parainfluenza
viru
ribavirin
activ
parainfluenza
virus
vitro
would
theoret
expect
activ
vivo
well
anecdot
report
immunodefici
children
sever
parainfluenza
viru
infect
suggest
aerosol
ribavirin
may
associ
antivir
effect
clinic
benefit
although
delay
treatment
aerosol
ribavirin
infant
born
prematur
also
risk
sever
diseas
perhap
lack
matern
antibodi
mortal
usual
previous
healthi
infant
hospit
rsv
diseas
primari
immunodefici
cancer
chemotherapi
pulmonari
heart
diseas
pulmonari
hypertens
associ
particularli
high
frequenc
poor
outcom
sever
diseas
also
associ
children
famili
histori
asthma
expos
cigarett
smoke
household
howev
import
recogn
major
hospit
rsv
previous
healthi
young
children
chest
radiograph
find
lower
respiratori
tract
diseas
includ
bronchial
wall
thicken
peribronchi
shadow
airtrap
efig
pneumonia
multilobar
patchi
shadow
poorli
defin
nodular
fig
efig
although
radiograph
pattern
specif
air
trap
alon
abnorm
highli
associ
rsv
infect
hospit
children
chest
ct
find
efig
rel
nonspecif
often
resembl
viral
pulmonari
infect
includ
multifoc
area
groundglass
opac
consolid
small
nodul
may
show
branch
configur
treeinbud
opac
common
physiolog
abnorm
hypoxemia
may
persist
week
appar
recoveri
prolong
pulmonari
function
abnorm
includ
increas
airway
resist
peripher
airway
obstruct
decreas
arteri
oxygen
satur
detect
children
year
bout
bronchiol
bronchiol
infanc
also
associ
increas
risk
subsequ
recurr
wheez
cough
airway
hyperreact
adult
one
half
recurr
infect
associ
upper
respiratori
tract
ill
adult
typic
experi
coryza
pharyng
cough
sometim
accompani
lowgrad
fever
bronchiti
influenzalik
ill
pneumonia
exacerb
asthma
chronic
bronchiti
also
describ
adult
rsv
infect
unit
state
approxim
hospit
death
associ
rsv
annual
adult
older
elderli
adult
clinic
featur
rsv
infect
mimic
influenza
although
fever
less
frequent
wheez
frequent
one
studi
rsv
infect
seen
healthi
elderli
highrisk
adult
annual
compar
influenza
icu
admiss
higher
mortal
similar
rsv
also
contribut
copd
exacerb
older
patient
sever
rsv
infect
longer
period
viral
shed
higher
level
mucos
higher
frequenc
circul
activ
cell
compar
young
patient
mild
diseas
suggest
viral
load
inflamm
may
play
role
diseas
sever
immunosuppress
children
adult
rsv
often
nosocomi
acquir
caus
sever
lower
respiratori
tract
diseas
upper
respiratori
tract
ill
usual
preced
develop
pneumonia
complic
sinus
otiti
media
common
two
third
bone
marrow
transplant
recipi
develop
rsv
pneumonia
die
infect
outbreak
day
care
center
commonli
hospit
staff
patient
epidem
period
famili
set
secondari
infect
develop
approxim
one
half
infant
one
third
adult
contact
introduct
viru
older
sibl
pathogenesi
viral
replic
gener
begin
upper
respiratori
tract
gradual
progress
involv
lower
respiratori
tract
children
normal
immun
durat
viral
shed
rang
week
clinic
sign
bronchiol
includ
airway
trap
wheez
patholog
find
rsv
bronchiol
includ
necrosi
bronchiolar
epithelium
loss
ciliat
epitheli
cell
mark
peribronchiolar
mononuclear
inflamm
virusinduc
cytopatholog
associ
submucos
edema
lead
obstruct
smaller
bronchiol
particularli
infant
distal
collaps
air
trap
serum
mucos
antibodi
respons
seen
associ
limit
protect
magnitud
antibodi
respons
relat
age
primari
infect
infant
younger
month
approxim
lower
antibodi
level
older
one
reinfect
may
take
place
within
week
primari
infect
circul
mucos
antibodi
level
increas
success
infect
appear
associ
milder
ill
high
titer
serum
neutral
antibodi
gener
associ
lower
risk
sever
ill
infant
children
cellmedi
immun
appear
import
viral
clearanc
may
also
involv
pathogenesi
exampl
adult
bone
marrow
transplant
patient
high
risk
sever
lower
respiratori
diseas
rsv
like
due
prolong
period
decreas
cellular
immun
contrast
aid
patient
decreas
cellular
immun
may
suffer
mild
diseas
viral
shed
continu
month
studi
investig
associ
sever
rsv
diseas
infant
genet
polymorph
implic
sever
candid
innat
adapt
immun
gene
includ
surfact
sever
cytokin
chemokin
gene
modul
sever
rsv
diseas
clinic
manifest
infect
depend
age
immunolog
state
host
infant
young
children
upper
respiratori
ill
accompani
fever
otiti
media
common
rsv
major
caus
lower
respiratori
tract
ill
infant
young
children
account
bronchiol
pneumonia
smaller
proport
croup
bronchiti
case
age
group
sever
infect
seen
infant
younger
month
almost
primari
infect
symptomat
associ
bronchiol
pneumonia
approxim
infect
result
hospit
one
ten
hospit
infant
requir
mechan
ventilatori
support
risk
hospit
sever
bronchiol
particularli
high
infant
congenit
heart
diseas
chronic
lung
diseas
immunodefici
addit
contrast
earlier
vaccin
experi
passiv
transfer
antibodi
rsv
f
protein
shown
highli
effect
mean
prevent
rsv
morbid
highrisk
children
current
commerci
avail
product
palivizumab
human
monoclon
antibodi
f
protein
administr
palivizumab
infant
prematur
bronchopulmonari
dysplasia
result
reduct
rsvrelat
hospit
lower
incid
icu
admiss
second
trial
administr
palivizumab
infant
children
hemodynam
signific
congenit
heart
diseas
well
toler
result
decreas
rsvassoci
hospit
prophylaxi
palivizumab
consid
infant
younger
month
chronic
lung
diseas
sever
enough
requir
medic
therapi
within
month
anticip
start
rsv
season
prophylaxi
palivizumab
rsvivig
given
infant
hemodynam
signific
congenit
heart
diseas
infant
born
week
gestat
prophylaxi
infant
week
gestat
depend
presenc
rsv
risk
factor
exposur
tobacco
smoke
attend
day
care
schoolag
sibl
household
congenit
airway
abnorm
palivizumab
shown
effect
therapi
establish
rsv
diseas
recommend
interrupt
nosocomi
transmiss
includ
handwash
decontamin
surfac
inanim
object
isol
infect
patient
use
dispos
eyenos
goggl
pediatr
staff
reduc
risk
nosocomi
rsv
infect
staff
patient
regular
use
gown
glove
possibl
mask
hospit
staff
care
infect
children
may
also
reduc
risk
nosocomi
rsv
spread
protect
isol
highrisk
infant
defer
elect
admiss
recommend
institut
outbreak
rsv
rhinovirus
rv
speci
enteroviru
genu
picornavirida
famili
rv
virion
nonenvelop
particl
nm
diamet
four
major
structur
protein
genom
rv
consist
singlestrand
rna
approxim
dalton
code
kd
protein
cleav
structur
unit
virion
rv
genom
found
homolog
polioviru
genom
polioviru
rv
differ
howev
construct
protein
shell
rv
loos
pack
result
sensit
inactiv
low
ph
polioviru
tightli
pack
provid
virion
resist
acid
inactiv
acid
sensit
rv
optimum
growth
c
c
thought
account
replic
nasal
passag
possibl
larg
airway
gi
tract
basi
sequenc
data
rhinoviru
group
three
genogroup
b
c
addit
three
four
protein
rv
shell
react
neutral
antibodi
form
basi
antigen
type
number
presenc
neutral
antibodi
serum
nasal
rapidli
readili
avail
approach
establish
rsv
infect
rapid
antigen
detect
sensit
techniqu
depend
qualiti
nasopharyng
specimen
nasopharyng
aspir
superior
brush
swab
addit
sensit
relat
amount
antigen
shed
gener
greater
children
adult
transplant
patient
suspect
rsv
pneumonia
sampl
lower
respiratori
tract
bal
sensit
throat
swab
detect
rsv
antigen
pcrbase
respiratori
viral
multiplex
assay
detect
rsv
respiratori
virus
also
approv
us
food
drug
administr
becom
wide
avail
see
chapter
rsv
grow
well
sever
human
cell
line
caus
format
characterist
syncytia
viru
detect
earli
day
usual
within
day
primari
isol
specimen
collect
children
correct
hypoxemia
import
aspect
manag
rsv
lower
respiratori
tract
diseas
ribavirin
highli
activ
rsv
vitro
aerosol
ribavirin
shown
reduc
viral
shed
shorten
cours
ill
studi
aerosol
ribavirin
current
recommend
use
select
infant
young
children
high
risk
seriou
rsv
diseas
immunosuppress
patient
particularli
hematopoiet
stem
cell
transplant
recipi
aerosol
ribavirin
highdos
oral
ribavirin
use
earli
treatment
prevent
progress
pneumonia
recent
studi
suggest
intermitt
aerosol
ribavirin
effect
continu
aerosol
ribavirin
patient
rsv
pneumonia
develop
intraven
ribavirin
alon
ineffect
treatment
initi
onset
respiratori
failur
combin
aerosol
ribavirin
intraven
immunoglobulin
particularli
paluvizumab
see
later
may
benefici
adult
short
cours
system
corticosteroid
rsvrelat
wheez
affect
viral
load
shed
mildli
diminish
antibodi
respons
effect
vaccin
prevent
rsv
yet
develop
studi
formalininactiv
rsv
vaccin
conduct
vaccin
infant
develop
sever
diseas
compar
unvaccin
children
mechan
enhanc
remain
uncertain
although
studi
vaccin
recipi
rodent
model
implic
low
level
low
affin
antibodi
induc
formalininactiv
vaccin
permit
excess
cytolyt
tcell
respons
develop
caus
tissu
damag
lowaffin
antibodi
may
also
contribut
immun
complex
format
deposit
lead
local
inflamm
formalininactiv
rsv
also
prime
helper
respons
high
level
interleukin
interleukin
promot
inflamm
small
airway
although
advers
experi
prompt
extra
caution
current
rsv
vaccin
develop
effort
ongo
focu
live
attenu
recombin
subunit
vaccin
introduc
home
infect
famili
member
studi
experiment
rv
cold
volunt
shown
rv
effici
spread
contamin
finger
accident
deposit
viru
nose
eye
experiment
rv
transmiss
also
achiev
airborn
rout
presum
largeparticl
aerosol
rel
import
two
rout
rv
transmiss
natur
condit
determin
approxim
two
third
natur
experiment
rv
infect
result
overt
ill
incub
period
rv
cold
usual
day
may
week
symptom
begin
within
day
follow
experiment
infect
small
dose
rv
instil
nose
eye
suscept
volunt
regularli
lead
infect
indic
mucociliari
clearanc
effect
viru
period
ill
slough
ciliat
epitheli
cell
contain
viral
antigen
present
nasal
secret
gener
number
rvinfect
cell
nasopharynx
appear
limit
infect
lead
detect
damag
epithelium
nasal
passag
result
suggest
virusinduc
cellular
injuri
direct
caus
symptom
rv
cold
inflammatori
mediat
play
import
role
nasal
secret
initi
respons
rv
infect
predominantli
result
increas
vascular
permeabl
demonstr
elev
level
plasma
protein
nasal
secret
glandular
secret
lactoferrin
lysozym
secretori
iga
predomin
late
cold
contrast
situat
allerg
rhiniti
histamin
appear
play
role
induct
symptom
cold
nasal
secret
kinin
level
correl
symptom
natur
experiment
cold
intranas
administr
bradykinin
caus
increas
nasal
vascular
permeabl
rhiniti
sore
throat
interleukin
il
concentr
also
increas
experiment
rv
cold
correl
well
symptom
sever
enhanc
synthesi
proinflammatori
cytokin
cell
adhes
molecul
middl
ear
may
also
contribut
pathogenesi
otiti
media
associ
cold
polymorph
gene
affect
symptomat
respons
experiment
rv
challeng
adult
rv
cold
vari
sever
mild
episod
character
day
coryza
scratchi
throat
fullblown
ill
profus
prolong
rhinorrhea
pharyng
bronchiti
profil
typic
rv
cold
base
composit
result
young
adult
natur
infect
shown
figur
median
length
ill
week
symptom
last
week
one
quarter
case
peak
symptom
usual
seen
second
third
day
ill
characterist
rv
ill
distinct
enough
permit
differenti
cold
due
respiratori
virus
rv
among
respiratori
virus
implic
develop
acut
sinus
repres
half
virus
recov
middl
ear
effus
children
acut
otiti
media
recent
clinic
present
indistinguish
influenza
also
report
healthi
adult
secret
correl
protect
infect
xray
diffract
studi
rv
disclos
presenc
larg
depress
surfac
viru
shell
junction
plateau
three
protein
fig
depress
contain
recognit
site
host
cell
receptor
intercellular
adhes
bind
known
rhinoviru
serotyp
rv
serotyp
bind
refer
minor
receptor
group
virus
appear
util
lowdens
lipoprotein
receptor
manipul
receptor
protein
explor
potenti
control
measur
rhinoviru
infect
rv
worldwid
distribut
unit
state
rv
observ
caus
infect
per
person
per
year
adult
rv
believ
produc
even
higher
infect
rate
children
lead
acquisit
antibodi
differ
rv
type
throughout
childhood
adolesc
peak
antibodi
preval
young
adult
immun
rv
type
specif
confer
longliv
protect
follow
infect
although
may
second
infect
viru
type
differ
immunotyp
circul
given
popul
appar
random
manner
unit
state
rv
infect
preval
earli
fall
late
spring
major
reservoir
rv
school
children
transmit
rv
infect
among
peer
classroom
highli
contagi
childhood
diseas
typic
caus
commun
outbreak
late
winter
earli
spring
month
temper
region
varicella
spread
rapidli
household
contact
attack
rate
nearli
within
week
consequ
adult
temper
area
experienc
infect
childhood
high
proport
adult
semitrop
tropic
area
remain
suscept
primari
infect
herp
zoster
nonseason
seen
person
age
although
incid
increas
almost
linearli
year
age
adult
experi
zoster
typic
singl
episod
fifth
decad
life
clinic
appar
reinfect
seen
vzv
although
viru
infrequ
recov
respiratori
secret
varicella
patient
epidemiolog
evid
indic
viru
spread
person
person
airborn
transmiss
cutan
lesion
may
also
sourc
infecti
viru
suscept
person
infect
contact
patient
varicella
less
often
herp
zoster
implement
vaccin
vzv
import
caus
nosocomi
outbreak
pediatr
ward
spread
smallparticl
aerosol
incub
period
varicella
averag
week
almost
case
varicella
develop
within
day
exposur
initi
portal
infect
respiratori
tract
virem
dissemin
lead
extens
cutan
mucou
membran
lesion
follow
infect
vzv
establish
latenc
posterior
dorsal
root
ganglia
reactiv
viru
replic
centrifug
spread
along
sensori
nerv
lead
uniqu
dermatom
distribut
shingl
zoster
immunocompromis
host
zoster
viru
may
dissemin
site
varicella
children
normal
immun
varicella
usual
associ
signific
system
respiratori
manifest
exanthem
typic
begin
around
scalp
head
subsequ
involv
trunk
extrem
lesion
progress
variou
stage
erythemat
macul
vesicl
pustul
crust
area
lesion
differ
stage
evolut
contrast
smallpox
diseas
varicella
often
confus
lesion
begin
face
spread
outwardli
extrem
adjac
lesion
stage
develop
children
suscept
adult
immunocompromis
particularli
defect
cell
mediat
immun
includ
hiv
infect
varicella
follow
sever
cours
continu
lesion
develop
particularli
involv
extrem
high
fever
viscer
involv
pneumonia
meningoenceph
hepat
common
pregnanc
sever
pneumonia
develop
approxim
varicella
case
viral
pneumonia
major
complic
varicella
normal
adult
frequenc
estim
higher
children
smoke
signific
risk
factor
pneumonia
associ
varicella
usual
appar
day
onset
rash
symptom
rv
alon
combin
bacteria
recov
aspir
obtain
direct
punctur
maxillari
sinus
patient
acut
sinus
mucos
thicken
andor
sinu
exud
observ
subject
acut
cold
abnorm
transient
uncompl
case
resolv
within
day
howev
clinic
manifest
acut
bacteri
sinus
seen
small
proport
individu
natur
occur
cold
presum
rv
infect
impair
mucociliari
clearanc
local
defens
sinu
caviti
allow
secondari
bacteri
invas
increas
evid
import
role
rhinovirus
lower
respiratori
tract
diseas
adult
children
rv
second
frequent
recogn
agent
associ
pneumonia
bronchiol
infant
young
children
commonli
caus
exacerb
preexist
airway
diseas
copd
cystic
fibrosi
cold
gener
sever
atop
individu
rhinovirus
major
caus
asthma
exacerb
children
histori
wheez
asthma
significantli
rvassoci
hospit
without
histori
rv
infect
may
also
associ
sever
lower
respiratori
tract
diseas
transplant
patient
case
associ
prolong
shed
virus
also
detect
lower
respiratori
tract
diseas
individu
hematolog
malign
often
conjunct
pathogen
rapid
test
detect
rv
nucleic
acid
avail
respiratori
viru
panel
see
chapter
gener
distinguish
rhinovirus
enterovirus
rv
isol
cell
cultur
usual
within
day
inocul
viru
present
nasopharyng
secret
highest
concentr
first
second
day
ill
may
shed
long
week
indic
identif
specif
serotyp
rhinoviru
isol
made
neutral
test
effect
therapi
rv
cold
current
avail
symptomat
treatment
individu
complaint
remedi
recommend
treatment
describ
section
common
cold
chapter
although
hand
wash
undoubtedli
import
prevent
transmiss
recent
studi
could
show
benefit
routin
hand
disinfect
prevent
rv
cold
mention
earlier
plethora
rhinoviru
serotyp
suggest
effect
vaccin
forthcom
forese
futur
advanc
understand
structur
molecular
biolog
rhinovirus
led
develop
number
strategi
antivir
intervent
includ
receptor
blockad
capsidbind
agent
howev
none
agent
reach
approv
clinic
use
varicellazost
viru
vzv
envelop
doublestrand
dna
viru
larg
genom
bp
varicella
affect
mortal
depend
degre
immunosuppress
rang
zero
rapid
diagnosi
herp
group
infect
establish
cytolog
examin
lesion
scrape
tzank
smear
other
sensit
lesion
vesicular
stage
direct
immunofluoresc
vzv
antigen
lesion
sensit
rapid
laboratori
test
viru
labil
isol
vesicular
fluid
first
day
varicella
normal
host
day
immunocompromis
host
patient
dissemin
zoster
direct
inocul
vesicular
fluid
onto
monolay
cell
cultur
human
embryon
lung
fibroblast
bedsid
increas
likelihood
isol
live
attenu
varicella
vaccin
gener
neutral
antibodi
recipi
also
gener
longliv
cytotox
tcell
respons
varicella
viru
vaccin
immunosuppress
children
includ
leukemia
safe
although
small
proport
children
experi
mild
varicellalik
clinic
syndrom
approxim
month
vaccin
healthi
immunosuppress
children
vaccin
highli
effect
prevent
varicella
efficaci
rate
two
dose
varicella
vaccin
administ
subcutan
recommend
children
month
older
adolesc
adult
without
evid
prior
immun
seconddos
catchup
vaccin
recommend
previous
receiv
singl
dose
vaccin
higherdos
live
vaccin
effect
restimul
virusspecif
cellular
immun
adult
reduc
frequenc
reactiv
well
clinic
sever
zoster
highdos
live
vaccin
recommend
singl
dose
healthi
individu
older
although
uncompl
varicella
children
usual
requir
specif
treatment
oral
acyclovir
initi
within
hour
rash
onset
reduc
number
lesion
durat
fever
heal
time
compar
placebo
children
adolesc
adult
sequenti
intraven
oral
acyclovir
use
therapi
varicella
immunocompromis
children
immunocompromis
patient
local
zoster
intraven
acyclovir
found
halt
dissemin
addit
oral
acyclovir
valacyclovir
famciclovir
effect
treatment
zoster
may
reduc
durat
postherpet
neuralgia
healthi
adult
intraven
acyclovir
mgkg
everi
hour
day
appear
efficaci
varicella
pneumonia
previous
healthi
adult
start
earli
viral
infect
import
caus
diseas
respiratori
tract
associ
substanti
morbid
mortal
age
group
clinic
syndrom
common
cold
pharyng
acut
bronchiti
influenzalik
ill
croup
includ
cough
dyspnea
pleurit
chest
pain
hemoptysi
physic
find
fever
tachypnea
often
modest
intens
rash
necessarili
correl
sever
pneumonia
characterist
chest
radiograph
pattern
diffus
nodular
mm
opac
fig
efig
may
resolv
miliari
calcifi
nodul
efig
hilar
lymphadenopathi
pleural
effus
peribronchi
opac
frequent
present
pulmonari
infarct
may
complic
clinic
pictur
chest
ct
patient
varicella
pneumonia
typic
show
multifoc
diffus
variabl
size
nodul
mm
may
circumscrib
poorli
defin
efig
groundglass
opac
halo
may
seen
around
nodul
pulmonari
function
studi
found
normal
expiratori
flow
valu
decreas
carbon
monoxid
diffus
capac
may
persist
month
howev
mani
individu
radiograph
chang
rel
asymptomat
herp
zoster
zoster
repres
reactiv
latent
viru
along
one
three
dermatom
adult
usual
associ
pain
thorac
dermatom
involv
one
half
case
prolong
sever
pain
postherpet
neuralgia
seriou
complic
increas
frequenc
older
zoster
present
often
receiv
immunosuppress
therapi
chemotherapi
malign
anatom
site
irradi
treatment
malign
depend
degre
immunosuppress
herp
zoster
may
develop
patient
cutan
dissemin
defin
lesion
outsid
primari
dermatom
develop
immunosuppress
patient
appar
normal
patient
zoster
associ
viscer
involv
includ
pneumon
well
hepat
meningoenceph
uveiti
approxim
one
half
bronchiol
pneumoniamay
caus
sever
differ
virus
major
respiratori
virus
may
caus
one
clinic
syndrom
increas
recognit
role
respiratori
virus
lower
respiratori
tract
diseas
immunocompromis
individu
grow
avail
molecular
diagnost
test
lead
mani
viral
diagnos
effect
vaccin
avail
prevent
diseas
due
viral
pathogen
includ
influenza
measl
mump
rubella
varicella
viru
antivir
agent
avail
includ
influenza
herp
virus
cytomegaloviru
varicellazost
viru
respiratori
viral
pathogen
neither
vaccin
antivir
current
avail
new
respiratori
virus
continu
emerg
interfac
human
anim
speci
recent
exampl
includ
avian
swine
influenza
virus
sever
acut
respiratori
syndrom
middl
east
respiratori
syndrom
hantaviru
pulmonari
syndrom
continu
surveil
new
agent
critic
control
pandem
assiri
yearold
woman
signific
previou
medic
histori
present
emerg
depart
fever
cough
nasal
congest
show
multifoc
perihilar
predominantli
linear
opac
bronchovascular
thicken
hazi
opac
patient
seen
outpati
treat
sever
broadspectrum
antibiot
improv
time
chest
radiograph
perform
patient
mildli
leukopen
oxygen
satur
room
air
axial
chest
ct
display
lung
window
show
multifoc
bilater
nonsegment
area
groundglass
opac
area
peripher
peribronchi
distribut
associ
intralobular
interstiti
thicken
mild
interlobular
septal
thicken
area
consolid
imag
find
nonspecif
seen
numer
caus
noninfecti
acut
lung
injuri
pulmonari
infect
includ
sever
acut
respiratori
syndrom
sar
surgic
lung
biopsi
show
diffus
alveolar
damag
intrabronchiolar
alveolar
inflammatori
cell
suggest
possibl
infecti
insult
bronchoscopi
surgic
biopsi
recov
influenza
patient
suffer
hypox
respiratori
failur
requir
mechan
ventil
subsequ
recov
